Data / Research funding / Pediatric Cancer
Pediatric Cancer: 1,837 NIH awards ($2.4B) to 303 organizations
1,837 NIH awards ($2.4B) in the NIH spending category Pediatric Cancer, to 303 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
The 500 largest of 1,837 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| COG NCTN Year 12 BIQSFP Progress Report | NIH | National Cancer Institute | 2021 to 2025 | $141,250,012 | April 11, 2014 | February 28, 2026 | HAWKINS, DOUGLAS S. | reporter.nih.gov |
| Pediatric HIV/AIDS Cohort Study (PHACS) 2020 | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2024 | $71,153,847 | September 18, 2020 | July 31, 2026 | WILLIAMS, PAIGE L | reporter.nih.gov |
| COG Biospecimen Bank to Support NCI NCTN (U24) | NIH | National Cancer Institute | 2021 to 2025 | $34,059,058 | April 22, 2015 | March 31, 2027 | RAMIREZ MILAN, NILSA DEL CARMEN | reporter.nih.gov |
| Children's Oncology Group | NIH | National Cancer Institute | 2023 to 2025 | $31,354,180 | March 1, 2023 | February 28, 2026 | ALONZO, TODD A | reporter.nih.gov |
| Children's Oncology Group NCI Community Oncology Research Program (NCORP) Research Base grant | NIH | National Cancer Institute | 2021 to 2025 | $27,607,459 | June 1, 2025 | July 31, 2026 | ROTH, MICHAEL E. | reporter.nih.gov |
| Childhood Cancer Survivorship Study | NIH | National Cancer Institute | 2021 to 2025 | $27,522,831 | July 20, 1993 | November 30, 2026 | ARMSTRONG, GREGORY | reporter.nih.gov |
| CCSG - Administrative Supplement - ECIA | NIH | National Cancer Institute | 2021 to 2025 | $22,920,176 | September 1, 1997 | March 31, 2029 | ODUNSI, KUNLE | reporter.nih.gov |
| Kids First Pediatric Data Resource Center | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2025 | $21,614,897 | September 1, 2025 | August 31, 2026 | RESNICK, ADAM CAIN | reporter.nih.gov |
| Cancer Center Support Grant | NIH | National Cancer Institute | 2021 to 2025 | $20,980,807 | December 1, 1996 | February 28, 2029 | MAITRA, ANIRBAN | reporter.nih.gov |
| Pediatric Brain Tumor Consortium A multi-institutional consortium devoted to novel phase I and II clinical evaluations of experimental treatment approaches for pediatric CNS tumors | NIH | National Cancer Institute | 2021 to 2025 | $18,653,803 | April 1, 1999 | March 31, 2026 | ONAR-THOMAS, ARZU | reporter.nih.gov |
| Tracking and Engaging Disconnected Long-Term Survivors of Childhood Cancer to Improve Adherence to Evidence-Based Screening Guidelines | NIH | National Cancer Institute | 2021 to 2025 | $14,573,097 | September 5, 1997 | August 31, 2026 | SWEASY, JOANN B. | reporter.nih.gov |
| Children's Oncology Group Pediatric Early Phase Clinical Trial Network | NIH | National Cancer Institute | 2021 to 2024 | $14,041,303 | May 3, 2024 | July 31, 2024 | WEIGEL, BRENDA J. | reporter.nih.gov |
| NATIONAL CHILDHOOD CANCER REGISTRY (NCCR) | NIH | National Cancer Institute | 2021 to 2025 | $12,616,798 | July 1, 2022 | June 30, 2025 | KOHLER, BETSY | reporter.nih.gov |
| Center for Live Cell Genomics | NIH | National Human Genome Research Institute | 2021 to 2025 | $11,992,289 | September 15, 2021 | June 30, 2027 | HAUSSLER, DAVID H | reporter.nih.gov |
| (EET Biobank) NCI Early-Phase and Experimental Clinical Trials Biospecimen Bank | NIH | National Cancer Institute | 2021 to 2025 | $11,843,510 | September 1, 2020 | March 31, 2027 | NICOL, KATHLEEN | reporter.nih.gov |
| Cancer Center Support (CORE) Grant | NIH | National Cancer Institute | 2021 to 2025 | $11,628,123 | August 1, 1997 | June 30, 2030 | PALUCKA, ANNA KAROLINA | reporter.nih.gov |
| Cancer Research Consortium of West Michigan (CRCWM) | NIH | National Cancer Institute | 2021 to 2025 | $11,366,311 | August 8, 2014 | July 31, 2026 | BUTLER, KATHLEEN YOST | reporter.nih.gov |
| Characterizing pediatric genomes through an optimized sequencing approach | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2024 | $11,335,114 | September 23, 2016 | August 31, 2025 | GRIMWOOD, JANE | reporter.nih.gov |
| Aurora NCORP Community Site | NIH | National Cancer Institute | 2021 to 2025 | $9,617,195 | August 15, 2014 | July 31, 2026 | SAPHNER, THOMAS J | reporter.nih.gov |
| Kids First Data Resource Center (KFDRC): Harnessing Data-Driven Opportunities in the Present on behalf of the Future of Common Fund Data Ecosystem (CFDE) | NIH | Office of the Director, National Institutes of Health | 2021 to 2025 | $8,664,754 | September 25, 2025 | March 24, 2027 | RESNICK, ADAM CAIN | reporter.nih.gov |
| Clinical Care Gaps and Unmet Needs in Adolescent and Young Adult (AYA) Cancers | NIH | National Cancer Institute | 2021 to 2025 | $8,380,255 | September 15, 2020 | June 30, 2027 | KUSHI, LAWRENCE H | reporter.nih.gov |
| CCDI SUPPORT FOR NIH/NCI/DCCPS SURVEILLANCE RESEARCH PROGRAM | NIH | National Cancer Institute | 2021 to 2025 | $8,176,428 | August 16, 2021 | August 15, 2026 | reporter.nih.gov | |
| Comparison of Symptom Burden/Toxicity, Neurocognitive Change, and Functional Outcomes in Pediatric Brain Tumor Patients Treated with Proton vs. Photon Radiotherapy. | NIH | National Cancer Institute | 2021 to 2025 | $6,769,276 | March 1, 2021 | August 31, 2027 | KAHALLEY, LISA SCHUM | reporter.nih.gov |
| CAUSAL: Cohort to Augment the Understanding of Sarcoma Survivorship Across the Lifespan | NIH | National Cancer Institute | 2023 to 2025 | $6,381,605 | September 22, 2021 | August 31, 2027 | FRIEDMAN, DEBRA L. | reporter.nih.gov |
| Translating genomic discoveries to improved outcomes for high risk acute leukemia | NIH | National Cancer Institute | 2021 to 2025 | $6,239,168 | January 19, 2017 | August 31, 2030 | MULLIGHAN, CHARLES G | reporter.nih.gov |
| Metabolic gatekeepers in B-cell malignancies | NIH | National Cancer Institute | 2021 to 2025 | $5,936,594 | April 1, 2016 | August 31, 2028 | MÜSCHEN, MARKUS | reporter.nih.gov |
| Pediatric Solid Tumor Microenvironment Atlas | NIH | National Cancer Institute | 2024 to 2025 | $5,678,350 | September 1, 2024 | August 31, 2029 | ASGHARZADEH, SHAHAB | reporter.nih.gov |
| MaineHealth Cancer Care Network (MHCCN) and NCORP Activities across the Lifespan | NIH | National Cancer Institute | 2021 to 2025 | $5,149,103 | August 13, 2019 | July 31, 2026 | REMICK, SCOT C | reporter.nih.gov |
| Survivorship and Access to care for Latinos to Understand and Address health outcome Differences (SALUD) | NIH | National Cancer Institute | 2023 to 2025 | $5,079,158 | May 10, 2021 | April 30, 2027 | GRAMATGES, MARIA MONICA | reporter.nih.gov |
| Identifying the mechanisms of leukemia progression | NIH | National Cancer Institute | 2021 to 2025 | $5,032,279 | September 22, 2021 | August 31, 2028 | CRISPINO, JOHN D | reporter.nih.gov |
| Puerto Rico NCI Community Oncology Research Program (Puerto Rico NCORP) | NIH | National Cancer Institute | 2021 to 2025 | $4,943,161 | August 22, 2014 | July 31, 2026 | SANTOS-REYES, LUIS JAVIER | reporter.nih.gov |
| The St. Jude Lifetime Cohort | NIH | National Cancer Institute | 2021 to 2024 | $4,907,509 | July 9, 2015 | June 30, 2025 | HUDSON, MELISSA M | reporter.nih.gov |
| Mechanistic studies of chromatin modification in transcription regulation | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $4,727,113 | February 14, 2019 | April 30, 2029 | WOLBERGER, CYNTHIA | reporter.nih.gov |
| Live-cell Activity Architecture in Cancer | NIH | National Cancer Institute | 2021 to 2025 | $4,655,641 | August 1, 2015 | July 31, 2029 | ZHANG, JIN | reporter.nih.gov |
| Mutations of Chromatin and its Modifying Machineries in Malignancies | NIH | National Cancer Institute | 2021 to 2025 | $4,635,274 | August 13, 2015 | August 31, 2029 | SHILATIFARD, ALI | reporter.nih.gov |
| Proteogenomic characterization of early and late resistance mechanisms in acute myeloid leukemia | NIH | National Cancer Institute | 2022 to 2025 | $4,603,890 | June 15, 2022 | May 31, 2027 | TYNER, JEFFREY WALLACE | reporter.nih.gov |
| Chemical Approaches to Modulate PAX3-FOXO1 in Fusion-Positive Alveolar Rhabdomyosarcoma | NIH | National Cancer Institute | 2024 to 2025 | $4,597,865 | September 6, 2024 | August 31, 2029 | KOEHLER, ANGELA NICOLE | reporter.nih.gov |
| Molecular and Cellular Regulation of Pre-Leukemic Stem Cells and their Therapeutic Targeting | NIH | National Cancer Institute | 2021 to 2025 | $4,594,192 | September 1, 2021 | August 31, 2028 | STEIDL, ULRICH | reporter.nih.gov |
| Molecular Pathogenesis of Acute Myeloid Leukemia | NIH | National Cancer Institute | 2021 to 2025 | $4,591,274 | August 13, 2015 | June 30, 2029 | LEY, TIMOTHY J. | reporter.nih.gov |
| Targeting transcriptional addiction in fusion-driven sarcoma | NIH | National Cancer Institute | 2024 to 2025 | $4,553,009 | July 8, 2024 | June 30, 2029 | MCFADDEN, DAVID GLENN | reporter.nih.gov |
| Therapeutic Targeting of Human AML Stem Cells | NIH | National Cancer Institute | 2021 to 2025 | $4,546,001 | September 8, 2020 | August 31, 2027 | JORDAN, CRAIG T. | reporter.nih.gov |
| Texas Pediatric NCORP | NIH | National Cancer Institute | 2021 to 2025 | $4,510,206 | August 1, 2014 | July 31, 2026 | LANGEVIN, ANNE-MARIE R. | reporter.nih.gov |
| U24-Uncovering the Shared Genetic Origins of Childhood Cancer and Structural Birth Defects Through Enhanced Data Integration and Analysis with the CFDE Data Distillery Knowledge Graph. | NIH | Office of the Director, National Institutes of Health | 2024 to 2025 | $4,408,884 | September 19, 2024 | August 31, 2027 | TAYLOR, DEANNE MARIE | reporter.nih.gov |
| Pediatric Early Phase Clinical Trials Network (PEP-CTN) Transfer Application | NIH | National Cancer Institute | 2025 | $4,394,441 | August 1, 2025 | July 31, 2029 | FOX, ELIZABETH | reporter.nih.gov |
| Pediatric Oncology In Vivo Testing Program Coordinating Center | NIH | National Cancer Institute | 2021 to 2025 | $4,288,627 | August 25, 2021 | June 30, 2026 | BULT, CAROL J | reporter.nih.gov |
| Patient Navigation for Improving Transition Success Among Multiply Disadvantaged Young Adult Survivors of Childhood Cancer | NIH | National Cancer Institute | 2025 | $4,236,812 | September 10, 2025 | August 31, 2029 | FREYER, DAVID R | reporter.nih.gov |
| Translating Pediatric Cancer Proteogenomic Data into Biological and Clinical Insights | NIH | National Cancer Institute | 2022 to 2025 | $4,071,173 | June 1, 2022 | May 31, 2027 | ZHANG, BING | reporter.nih.gov |
| Combining Targeted RIT and Synergistic Novel Agent-Renewal | NIH | National Cancer Institute | 2021 to 2025 | $3,984,924 | June 1, 2020 | May 31, 2027 | OROZCO, JOHNNIE JOSE | reporter.nih.gov |
| Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex Sequencing | NIH | National Cancer Institute | 2021 to 2025 | $3,984,664 | July 16, 2018 | January 31, 2027 | BICKEL, KELLIE | reporter.nih.gov |
| NextGen - CRI | NIH | National Cancer Institute | 2022 to 2025 | $3,968,330 | June 1, 2025 | May 31, 2026 | BOLLARD, CATHERINE M. | reporter.nih.gov |
| Discovering mechanisms of neuroblastoma tumorigenesis to improve patient outcomes | NIH | National Cancer Institute | 2021 to 2025 | $3,932,444 | September 30, 2017 | August 31, 2032 | MARIS, JOHN M | reporter.nih.gov |
| Prevalence and persistence of the ETV6/RUNX1 pre-leukemic clone | NIH | National Cancer Institute | 2023 to 2025 | $3,924,430 | September 1, 2023 | August 31, 2028 | MARCOTTE, ERIN | reporter.nih.gov |
| Cooperative Human Tissue Network | NIH | National Cancer Institute | 2021 to 2025 | $3,922,198 | April 16, 2019 | March 31, 2029 | RAMIREZ MILAN, NILSA DEL CARMEN | reporter.nih.gov |
| CCL2 and CCR2 as metastatic drivers and therapeutic targets in medulloblastoma | NIH | National Cancer Institute | 2021 to 2025 | $3,903,008 | January 1, 2021 | December 31, 2025 | WEISS, WILLIAM A | reporter.nih.gov |
| Physician Scientist Training in Clinical Oncology | NIH | National Cancer Institute | 2021 to 2025 | $3,870,097 | September 30, 1997 | June 30, 2030 | SCHUCHTER, LYNN M. | reporter.nih.gov |
| Elucidating and Targeting tumor dependencies and drug resistance determinants at the single cell level | NIH | National Cancer Institute | 2022 to 2025 | $3,840,901 | September 21, 2022 | August 31, 2027 | CALIFANO, ANDREA | reporter.nih.gov |
| In vivo Drug Testing of Pediatric CNS Tumors Using Patient Derived Orthotopic Xenograft Models | NIH | National Cancer Institute | 2021 to 2025 | $3,829,886 | July 14, 2015 | June 30, 2026 | LI, XIAONAN | reporter.nih.gov |
| PEDIATRIC ONCOLOGY CLINICAL RESEARCH TRAINING PROGRAM | NIH | National Cancer Institute | 2021 to 2025 | $3,805,840 | July 1, 2002 | June 30, 2027 | ALLEN, CARL E | reporter.nih.gov |
| GEMS: Genomic approach to connecting Elevated germline Mutation rates with male infertility and Somatic health | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $3,803,952 | September 1, 2021 | May 31, 2027 | HOTALING, JAMES | reporter.nih.gov |
| Enhance UCSC Xena: extend interactive visualization to ultra-large-scale multi-omics data and integrate with analysis resources | NIH | National Cancer Institute | 2021 to 2025 | $3,765,580 | September 1, 2021 | August 31, 2027 | ZHU, JINGCHUN | reporter.nih.gov |
| Social genomic mechanisms of health disparities among Adolescent and Young Adult (AYA) cancer survivors | NIH | National Cancer Institute | 2021 to 2025 | $3,743,381 | September 10, 2021 | August 31, 2027 | ZEBRACK, BRADLEY JAY | reporter.nih.gov |
| Proteogenomic translator for cancer biomarker discovery towards precision medicine | NIH | National Cancer Institute | 2022 to 2025 | $3,707,896 | May 1, 2025 | April 30, 2026 | WANG, PEI | reporter.nih.gov |
| Characterization of brain dysfunction during development in survivors of childhood acute lymphoblastic leukemia | NIH | National Cancer Institute | 2021 to 2024 | $3,657,208 | March 1, 2020 | February 28, 2026 | SUSSMAN, ELYSE S | reporter.nih.gov |
| Michigan Center for Translational Cancer Proteogenomics | NIH | National Cancer Institute | 2022 to 2025 | $3,656,494 | June 6, 2022 | May 31, 2027 | NESVIZHSKII, ALEXEY I | reporter.nih.gov |
| Nemours NCI Community Oncology Research Program (NCORP) | NIH | National Cancer Institute | 2021 to 2025 | $3,654,103 | June 2, 2025 | July 31, 2026 | CAYWOOD, EMI H | reporter.nih.gov |
| Pediatric Preclinical In Vivo Testing Center for Pediatric Sarcoma and Other Solid Tumors | NIH | National Cancer Institute | 2021 to 2025 | $3,652,183 | July 1, 2021 | June 30, 2026 | KUNG, ANDREW L | reporter.nih.gov |
| In Vivo Testing of Novel Drug Combinations for Pediatric Soft Tissue Sarcomas | NIH | National Cancer Institute | 2021 to 2025 | $3,632,740 | July 1, 2021 | June 30, 2027 | DYER, MICHAEL A | reporter.nih.gov |
| NGTC - UCL | NIH | National Cancer Institute | 2022 to 2024 | $3,627,871 | June 1, 2024 | May 31, 2025 | PULE, MARTIN | reporter.nih.gov |
| HCMV-induced innate-like CD8 T cells and allogeneic HCT outcome | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,601,018 | April 9, 2021 | March 31, 2027 | HSU, KATHARINE C | reporter.nih.gov |
| Predicting and Preventing Chemotherapy-Induced Cardiotoxicity in African American Children | NIH | National Cancer Institute | 2021 to 2025 | $3,570,931 | August 5, 2021 | July 31, 2026 | BURRIDGE, PAUL W. | reporter.nih.gov |
| NCI Pediatric In Vivo Testing Program: Neuroblastoma | NIH | National Cancer Institute | 2021 to 2025 | $3,549,742 | July 1, 2021 | June 30, 2027 | MOSSE, YAEL P | reporter.nih.gov |
| The Florida Pediatric NCORP: NCI Community Oncology Research Program. | NIH | National Cancer Institute | 2021 to 2025 | $3,543,398 | June 1, 2025 | July 31, 2026 | SALMAN, EMAD | reporter.nih.gov |
| SALSA - Study of Active Lifestyle Activation | NIH | National Cancer Institute | 2021 to 2025 | $3,527,531 | September 21, 2021 | August 31, 2026 | CHOW, ERIC JESSEN | reporter.nih.gov |
| Identifying Relapse Predictors and Therapeutic Vulnerabilities in Ph+ and Ph-like Acute Lymphoblastic Leukemia | NIH | National Cancer Institute | 2025 | $3,480,276 | August 1, 2025 | July 31, 2029 | LOH, MIGNON LEE-CHEUN | reporter.nih.gov |
| Intensive tailored exercise training with NAD+ precursor supplementation to improve muscle mass and fitness in adolescent and young adult survivors of hematopoietic stem cell transplantation | NIH | National Cancer Institute | 2021 to 2025 | $3,469,202 | September 1, 2021 | August 31, 2027 | MOSTOUFI-MOAB, SOGOL | reporter.nih.gov |
| Leveraging Digital Health Solutions to Reduce Learning and Functional Disparities in Children with Cancer - Administrative Supplement | NIH | National Cancer Institute | 2022 to 2025 | $3,407,172 | July 5, 2022 | June 30, 2027 | PATEL, SUNITA K | reporter.nih.gov |
| Individual, cultural, and area-based factors associated with survivorship care among Asian/Asian American childhood cancer survivors | NIH | National Cancer Institute | 2021 to 2025 | $3,406,825 | September 6, 2021 | August 31, 2027 | MILLER, KIMBERLY ANN | reporter.nih.gov |
| Mitigating Long-term Treatment-related Morbidity in Childhood Cancer Survivors | NIH | National Cancer Institute | 2021 to 2024 | $3,381,151 | September 1, 2018 | August 31, 2025 | BHATIA, SMITA | reporter.nih.gov |
| Development of Potent, Selective, Non-Myelotoxic FLT3 Inhibitors that Retain Efficacy Against Common Mechanisms of Resistance | NIH | National Cancer Institute | 2021 to 2025 | $3,350,719 | December 15, 2020 | November 30, 2025 | SHAH, NEIL P | reporter.nih.gov |
| Targeting DKK-1 To Prevent Osteosarcoma Metastasis | NIH | National Cancer Institute | 2021 to 2025 | $3,331,390 | July 9, 2021 | June 30, 2026 | LOEB, DAVID M. | reporter.nih.gov |
| Career Development in Pediatric and Medical Oncology | NIH | National Cancer Institute | 2021 to 2025 | $3,314,336 | September 30, 1997 | August 31, 2026 | MESHINCHI, SOHEIL | reporter.nih.gov |
| Theranostics for Pediatric Brain Cancer | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $3,299,320 | April 15, 2021 | January 31, 2027 | DALDRUP-LINK, HEIKE ELIZABETH | reporter.nih.gov |
| Developing Safe and Effective GD2-CAR T Cell Therapy for Diffuse Midline Gliomas | NIH | National Cancer Institute | 2021 to 2025 | $3,294,656 | August 6, 2021 | July 31, 2026 | MACKALL, CRYSTAL | reporter.nih.gov |
| BRidging Information Divides and Gaps to Ensure Survivorship: the BRIDGES Randomized Controlled Trial of a Multilevel Intervention to Improve Adherence to Childhood Cancer Survivorship | NIH | National Cancer Institute | 2021 to 2025 | $3,225,740 | September 21, 2021 | August 31, 2027 | KADAN-LOTTICK, NINA S | reporter.nih.gov |
| Optimization of a mHealth Physical Activity Promotion Intervention with Mindful Awareness for Adolescent and Young Adult Cancer Survivors | NIH | National Cancer Institute | 2021 to 2025 | $3,207,908 | September 1, 2021 | July 31, 2026 | PHILLIPS, SIOBHAN MARIE | reporter.nih.gov |
| NATIONAL CHILDHOOD CANCER REGISTRY (NCCR) DATA PLATFORM | NIH | National Cancer Institute | 2022 | $3,205,546 | September 16, 2022 | September 15, 2024 | STOWE, JORDAN | reporter.nih.gov |
| Discovery of First-in-class WDR5 PROTACs as a Novel Therapeutic Strategy for MLL-rearranged Leukemias | NIH | National Cancer Institute | 2022 to 2025 | $3,200,543 | May 1, 2022 | April 30, 2027 | JIN, JIAN | reporter.nih.gov |
| Co-Clinical Research Resource for Imaging Tumor Associated Macrophages | NIH | National Cancer Institute | 2021 to 2025 | $3,191,659 | September 15, 2021 | August 31, 2026 | DALDRUP-LINK, HEIKE ELIZABETH | reporter.nih.gov |
| Social Health, Activity Behaviors, and Quality of Life among Young Adult Cancer Survivors: A Longitudinal Study | NIH | National Cancer Institute | 2021 to 2025 | $3,178,150 | March 1, 2021 | February 28, 2026 | MILLER, KIMBERLY ANN | reporter.nih.gov |
| Targeting Pediatric Cancer Vulnerabilities | NIH | National Cancer Institute | 2023 to 2025 | $3,144,539 | September 19, 2023 | August 31, 2030 | STEGMAIER, KIMBERLY | reporter.nih.gov |
| Psychosocial Risk in Young Survivors of Early Onset Pediatric Cancer: The Role of Physical and Neurocognitive Late Effects | NIH | National Cancer Institute | 2021 to 2025 | $3,130,357 | February 9, 2021 | January 31, 2027 | GERHARDT, CYNTHIA A | reporter.nih.gov |
| Lab Research Training in Pediatric Oncology-Hematology | NIH | National Cancer Institute | 2021 to 2025 | $3,128,223 | September 30, 1993 | July 31, 2028 | FRIEDMAN, ALAN D | reporter.nih.gov |
| Culturally adapted mobile treatment of chronic pain in adolescent survivors of pediatric bone sarcoma | NIH | National Cancer Institute | 2025 | $3,128,074 | September 20, 2022 | May 31, 2028 | BRINKMAN, TARA M | reporter.nih.gov |
| Gvl mHA Specific T Cell Responses Prevent AML Relapse Following Allogeneic Stem Cell Transplantation. | NIH | National Cancer Institute | 2021 to 2025 | $3,119,515 | July 1, 2020 | June 30, 2027 | VINCENT, BENJAMIN G | reporter.nih.gov |
| Targeting CDK6 expression/activity in Ph+ and Ph1-like acute lymphoblastic leukemia (ALL) | NIH | National Cancer Institute | 2021 to 2025 | $3,113,868 | July 1, 2021 | June 30, 2027 | CALABRETTA, BRUNO | reporter.nih.gov |
| PROTECT (Harnessing PROTEin degradation for Advanced Childhood Tumors) | NIH | National Cancer Institute | 2024 to 2025 | $3,108,431 | May 1, 2024 | April 30, 2026 | STEGMAIER, KIMBERLY | reporter.nih.gov |
| Leveraging canine spontaneous cancer to optimize the power of blood biopsy | NIH | National Cancer Institute | 2021 to 2025 | $3,095,555 | June 7, 2021 | May 31, 2027 | KARLSSON, ELINOR | reporter.nih.gov |
| Assessing the effect of virtual navigation interventions to improve health insurance literacy and decrease financial burden: A CCSS randomized trial | NIH | National Cancer Institute | 2022 to 2025 | $3,070,648 | June 1, 2022 | March 31, 2027 | PARK, ELYSE R. | reporter.nih.gov |
| Predicting Relapse at the Time of Diagnosis in Acute Lymphoblastic Leukemia | NIH | National Cancer Institute | 2021 to 2025 | $3,056,754 | April 1, 2021 | March 31, 2027 | DAVIS, KARA LYNN | reporter.nih.gov |
| Dynamic 3D chromatin remodeling in acute leukemia - Resubmission - 1 | NIH | National Cancer Institute | 2021 to 2025 | $3,027,488 | April 1, 2021 | June 30, 2026 | TSIRIGOS, ARISTOTELIS | reporter.nih.gov |
| Cancer Immunotherapy Trials Network Central Operations and Statistical Center | NIH | National Cancer Institute | 2021 to 2022 | $2,997,769 | September 22, 2010 | August 31, 2023 | DAVIDSON, NANCY ELLEN | reporter.nih.gov |
| Adhesion GPCR regulation of acute myeloid leukemia stem cells - Resubmission - 1 | NIH | National Cancer Institute | 2021 to 2025 | $2,988,590 | March 1, 2021 | February 28, 2026 | PARK, CHRISTOPHER Y | reporter.nih.gov |
| NOVOMEDIX TRANSITION TO PHASE II - THERAPEUTICS SBIR CONTRACTSBIR PHASE II - ENHANCED OVERALL SURVIVAL IN HIGH-RISK PEDIATRIC SOLID TUMORS USING A NOVEL ORAL SMALL MOLECULE | NIH | National Cancer Institute | 2025 | $2,977,013 | September 15, 2025 | September 14, 2027 | reporter.nih.gov | |
| Biomarkers of dasatinib response and resistance in T-cell acute lymphoblastic leukemia | NIH | National Cancer Institute | 2021 to 2025 | $2,961,810 | July 1, 2021 | June 30, 2026 | YANG, JUN J. | reporter.nih.gov |
| Behavioral Parenting Skills as a Novel Target for Improving Pediatric Medication Adherence | NIH | National Cancer Institute | 2022 to 2025 | $2,958,176 | December 15, 2021 | November 30, 2026 | BOUCHARD, ELIZABETH | reporter.nih.gov |
| FEN1-Nuclease-Targeted Therapy for Ewing Sarcoma | NIH | National Cancer Institute | 2021 to 2025 | $2,946,641 | April 1, 2021 | March 31, 2027 | KOLODNER, RICHARD D | reporter.nih.gov |
| Personalized Risk Prediction to Reduce Cardiovascular Disease in Childhood Cancer Survivors | NIH | National Cancer Institute | 2022 to 2025 | $2,933,453 | July 15, 2022 | April 30, 2027 | HOWELL, REBECCA MAUREEN | reporter.nih.gov |
| The Evolution of Sarcoma Drug Sensitivity through Time and Space | NIH | National Cancer Institute | 2021 to 2024 | $2,930,546 | July 1, 2020 | June 30, 2025 | SORAGNI, ALICE | reporter.nih.gov |
| Backtracking Leukemia-Typical Somatic Alterations in Cord Blood at Single-cell Resolution | NIH | National Cancer Institute | 2021 to 2025 | $2,927,357 | August 1, 2021 | July 31, 2026 | SPECTOR, LOGAN G. | reporter.nih.gov |
| Enhancing B7-H3-CAR T cell therapy for pediatric solid tumors | NIH | National Cancer Institute | 2022 to 2025 | $2,924,883 | March 1, 2022 | February 28, 2027 | DERENZO, CHRISTOPHER | reporter.nih.gov |
| Information flow and state transitions at the system and multi-dimensional scales in leukemia progression | NIH | National Cancer Institute | 2021 to 2024 | $2,901,922 | May 1, 2020 | April 30, 2025 | ROCKNE, RUSSELL CHRISTIAN | reporter.nih.gov |
| Patient-Generated Health Data to Predict Childhood Cancer Survivorship Outcomes | NIH | National Cancer Institute | 2021 to 2025 | $2,900,455 | July 5, 2021 | June 30, 2027 | HUANG, I-CHAN | reporter.nih.gov |
| The synergistic contributions of EBV and malaria to the etiology of Burkitt lymphoma | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,895,508 | December 12, 2019 | January 31, 2025 | SAMAYOA REYES, GABRIELA M | reporter.nih.gov |
| Overcoming metastatic spread of osteosarcoma with RNA loaded nanoparticles | NIH | National Cancer Institute | 2022 to 2025 | $2,889,170 | September 1, 2022 | August 31, 2027 | SAYOUR, ELIAS | reporter.nih.gov |
| DREAM: Discovering cancer Risks from Environmental contaminants And Maternal/child health | NIH | National Cancer Institute | 2021 to 2024 | $2,883,502 | September 20, 2021 | August 31, 2025 | REYNOLDS, PEGGY | reporter.nih.gov |
| Metabolic control of normal and malignant hematopoiesis | NIH | National Cancer Institute | 2021 to 2025 | $2,869,404 | September 1, 2020 | May 31, 2027 | INTLEKOFER, ANDREW MICHAEL | reporter.nih.gov |
| Predictors of Systemic Exposure to Oral 6MP During Maintenance in Adolescentsand Young Adults with Acute Lymphoblastic Leukemia | NIH | National Cancer Institute | 2021 to 2025 | $2,864,905 | March 24, 2021 | February 28, 2027 | WOLFSON, JULIE ANNA | reporter.nih.gov |
| A Testing Program to Identify Novel Agents for Treatment of Pediatric and AYA High-Risk Sarcoma, Kidney and Liver Cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,862,121 | September 1, 2021 | June 30, 2026 | KURMASHEVA, RAUSHAN | reporter.nih.gov |
| Advanced Imaging Tools to Assess Cancer Therapeutics in Pediatric | NIH | National Cancer Institute | 2022 to 2025 | $2,853,545 | February 11, 2022 | June 30, 2027 | DALDRUP-LINK, HEIKE ELIZABETH | reporter.nih.gov |
| Neoantigen-specific T cell responses for Fibrolamellar Hepatocellular Carcinoma | NIH | National Cancer Institute | 2022 to 2025 | $2,835,203 | May 1, 2022 | April 30, 2027 | YARCHOAN, MARK | reporter.nih.gov |
| Inducing Neural Maturation in Medulloblastoma by Targeting EZH2 | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $2,801,562 | September 15, 2022 | August 31, 2026 | SNUDERL, MATIJA | reporter.nih.gov |
| Next Generation GPC2-CARs for Medulloblastoma | NIH | National Cancer Institute | 2024 to 2025 | $2,781,440 | September 13, 2024 | August 31, 2026 | MACKALL, CRYSTAL | reporter.nih.gov |
| Clonal Therapy for Pediatric T-cell Acute Lymphoblastic Leukemia | NIH | National Cancer Institute | 2021 to 2025 | $2,776,588 | September 16, 2021 | August 31, 2026 | YU, JIYANG | reporter.nih.gov |
| KSHV Latency Regulation | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,766,879 | November 5, 2021 | October 31, 2026 | KAYE, KENNETH M | reporter.nih.gov |
| Base-Edited Hematopoietic Stem and Progenitor Cells To Enable Safe Use Of Highly Potent CD33-Targeted Radioimmunotherapy | NIH | National Cancer Institute | 2022 to 2025 | $2,758,516 | July 1, 2022 | June 30, 2027 | WALTER, ROLAND BRUNO | reporter.nih.gov |
| Enhancing MAPK-targeted Therapy in PDX Models of BRAF-Mutant Pediatric Brain Tumors | NIH | National Cancer Institute | 2021 to 2025 | $2,752,745 | March 8, 2021 | February 28, 2026 | BURMA, SANDEEP | reporter.nih.gov |
| Image-guided combination therapies for radiotherapy-induced neurocognitive impairment in pediatric brain tumor survivors | NIH | National Cancer Institute | 2021 to 2025 | $2,750,972 | July 12, 2021 | June 30, 2027 | NGEN, ETHEL JOSO | reporter.nih.gov |
| Conformal Total Body and Marrow Irradiation for Leukemia | NIH | National Cancer Institute | 2021 to 2024 | $2,727,228 | September 13, 2011 | December 31, 2025 | HUI, SUSANTA K | reporter.nih.gov |
| Dysregulation of the Core Binding Factor Complex Inhibits Differentiation and Drives Group 4 Medulloblastoma | NIH | National Cancer Institute | 2022 to 2025 | $2,726,662 | April 4, 2011 | August 31, 2027 | WECHSLER-REYA, ROBERT J. | reporter.nih.gov |
| Can risk-reducing medications improve breast cancer prevention in childhood and adolescent cancer survivors? Comparative modeling to inform care | NIH | National Cancer Institute | 2022 to 2025 | $2,726,647 | September 1, 2022 | August 31, 2027 | YEH, JENNIFER M. | reporter.nih.gov |
| The ASPIRES Study: Activating Cancer Survivors and their Primary Care Providers to Increase Colorectal Cancer Screening | NIH | National Cancer Institute | 2021 to 2025 | $2,725,531 | March 1, 2021 | March 31, 2025 | HENDERSON, TARA OLIVE | reporter.nih.gov |
| Bispecific Antibody Therapeutics for Neuroblastoma and Diffuse Midline Glioma | NIH | National Cancer Institute | 2023 to 2025 | $2,724,833 | August 1, 2023 | July 31, 2028 | OLSON, JAMES M | reporter.nih.gov |
| Identifying therapeutic pathways targeting medulloblastoma-immune cell interactions | NIH | National Cancer Institute | 2021 to 2025 | $2,721,281 | May 1, 2021 | April 30, 2027 | FRAENKEL, ERNEST | reporter.nih.gov |
| EXPLORE AND TARGET THE EPIGENETIC VULNERABILITY OF PAX3-FOXO1-DRIVEN RHABDOMYOSARCOMA | NIH | National Cancer Institute | 2022 to 2025 | $2,717,300 | July 1, 2022 | June 30, 2027 | YANG, JUN | reporter.nih.gov |
| BAF complex deregulation in lymphoma | NIH | National Cancer Institute | 2022 to 2025 | $2,711,912 | August 2, 2022 | July 31, 2027 | GREEN, MICHAEL RICHARD | reporter.nih.gov |
| Understanding the Increased Risk of Childhood Acute Lymphoblastic Leukemia in Latinos | NIH | National Cancer Institute | 2022 to 2025 | $2,704,822 | May 1, 2022 | April 30, 2026 | DE SMITH, ADAM | reporter.nih.gov |
| Utility of memantine in preventing cognitive dysfunction in children receiving cranial radiotherapy | NIH | National Cancer Institute | 2022 to 2025 | $2,688,046 | September 18, 2019 | December 31, 2026 | LAACK, NADIA N | reporter.nih.gov |
| Targeting Defective DNA Damage Response Pathways in IDH1/2-mutant AML | NIH | National Cancer Institute | 2022 to 2025 | $2,684,963 | February 3, 2022 | January 31, 2027 | BINDRA, RANJIT | reporter.nih.gov |
| Implementation of an interventional, risk-adapted clinical trial for children with newly diagnosed juvenile myelomonocytic leukemia. | NIH | National Cancer Institute | 2022 to 2025 | $2,677,641 | August 1, 2022 | July 31, 2027 | STIEGLITZ, ELLIOT | reporter.nih.gov |
| How the 3D Architecture of the Brain Shapes Cancer Cell Fate Decisions | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $2,670,000 | September 30, 2021 | August 31, 2026 | FILBIN, MARIELLA GRUBER | reporter.nih.gov |
| Sustainability determinants of an intervention to identify clinical deterioration and improve childhood cancer survival in low-resource hospitals | NIH | National Cancer Institute | 2023 to 2025 | $2,669,584 | April 1, 2023 | March 31, 2028 | AGULNIK, ASYA | reporter.nih.gov |
| Mechanisms and therapeutic implications of human clonal hematopoiesis (CH) mutations | NIH | National Cancer Institute | 2022 to 2025 | $2,657,718 | June 15, 2022 | May 31, 2027 | PAPAPETROU, EIRINI | reporter.nih.gov |
| Generation of tumor specific immunity in canine osteosarcoma through dendritic cell hyperactivation | NIH | National Cancer Institute | 2022 to 2025 | $2,656,507 | September 1, 2022 | August 31, 2027 | LONDON, CHERYL A | reporter.nih.gov |
| Remodeling the translatome in N-myc mediated medulloblastoma and its therapeutic implications | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $2,644,746 | August 1, 2022 | July 31, 2027 | WEISS, WILLIAM A | reporter.nih.gov |
| Promoting Resilience in Early Survivorship among Adolescents and Young Adults with Cancer | NIH | National Cancer Institute | 2023 to 2025 | $2,642,459 | March 10, 2022 | February 28, 2027 | ROSENBERG, ABBY R | reporter.nih.gov |
| eHealth Intervention for Late Effects of Childhood Cancer | NIH | National Cancer Institute | 2021 to 2024 | $2,636,602 | September 1, 2019 | February 28, 2026 | BRINKMAN, TARA M | reporter.nih.gov |
| Liquid biopsy approaches to inform neuroblastoma prognosis and disease monitoring | NIH | National Cancer Institute | 2022 to 2025 | $2,631,965 | April 11, 2022 | March 31, 2027 | APPLEBAUM, MARK ANDREW | reporter.nih.gov |
| Targeting Latency Switch in EBV+ Lymphomas | NIH | National Cancer Institute | 2022 to 2025 | $2,611,281 | July 1, 2022 | June 30, 2027 | ROTH, LISA GIULINO | reporter.nih.gov |
| Personalized neuroblastoma vaccines | NIH | National Cancer Institute | 2023 to 2025 | $2,604,046 | August 1, 2023 | July 31, 2028 | MARIS, JOHN M | reporter.nih.gov |
| Improving Delivery of Genetic Services to High Risk Childhood Cancer Survivors: A Randomized Study of Remote Genetic Services Versus Usual Care | NIH | National Cancer Institute | 2021 to 2024 | $2,593,712 | July 8, 2020 | June 30, 2025 | HENDERSON, TARA OLIVE | reporter.nih.gov |
| A randomized controlled trial of eSCCIP: An eHealth psychosocial intervention for English and Spanish speaking parents of children with cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,563,585 | February 2, 2022 | January 31, 2027 | CANTER, KIMBERLY | reporter.nih.gov |
| Membrane protein target for leukemia therapy | NIH | National Cancer Institute | 2021 to 2025 | $2,553,914 | September 1, 2020 | July 31, 2027 | KANG, XUNLEI | reporter.nih.gov |
| Selectively Targeting Oncogenic NRAS in Cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,550,975 | April 1, 2015 | March 31, 2027 | SHANNON, KEVIN M. | reporter.nih.gov |
| Development of a Phenotype-based Predictive Analytic for Acute Myeloid Leukemia | NIH | National Cancer Institute | 2021 to 2025 | $2,544,479 | September 15, 2021 | February 28, 2027 | SAVONA, MICHAEL R | reporter.nih.gov |
| Development of Novel PROTACs Targeting the ENL YEATS Domain for Treating MLL-rearranged Leukemias | NIH | National Cancer Institute | 2021 to 2025 | $2,540,823 | April 1, 2021 | March 31, 2027 | JIN, JIAN | reporter.nih.gov |
| Psychosocial Stress Exacerbates Doxorubicin-induced Cardiovascular Aging | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,538,575 | April 10, 2020 | March 31, 2026 | ZORDOKY, BESHAY | reporter.nih.gov |
| Socioeconomic determinants of childhood cancer outcomes in a large contemporary cohort | NIH | National Cancer Institute | 2022 to 2025 | $2,536,169 | February 1, 2022 | January 31, 2027 | MARCOTTE, ERIN | reporter.nih.gov |
| COG NCTN Integrated Translational Science Center for Hematopoietic Malignancies in Children | NIH | National Cancer Institute | 2022 to 2025 | $2,523,182 | March 1, 2022 | February 28, 2026 | MESHINCHI, SOHEIL | reporter.nih.gov |
| Dissecting innate immune signaling in pre-leukemia evolution | NIH | National Cancer Institute | 2022 to 2025 | $2,523,046 | March 4, 2022 | February 28, 2027 | STARCZYNOWSKI, DANIEL | reporter.nih.gov |
| Neuronal Regulation of Low-Grade Gliomagenesis | NIH | National Cancer Institute | 2022 to 2025 | $2,518,768 | April 1, 2022 | March 31, 2027 | MONJE-DEISSEROTH, MICHELLE | reporter.nih.gov |
| Targeting the Metabolic Regulator SIRT5 in Acute Myeloid Leukemia | NIH | National Cancer Institute | 2021 to 2024 | $2,518,197 | July 1, 2020 | June 30, 2025 | DEININGER, MICHAEL W. | reporter.nih.gov |
| Dysregulation of Innate Lymphoid Immunity in Acute Myeloid Leukemia | NIH | National Cancer Institute | 2021 to 2025 | $2,498,906 | September 1, 2021 | August 31, 2027 | MUNDY-BOSSE, BETHANY | reporter.nih.gov |
| IL-15 and -21 armored GPC3-specific CAR T cells for children with solid tumors | NIH | National Cancer Institute | 2022 to 2025 | $2,490,304 | January 17, 2022 | October 31, 2025 | HECZEY, ANDRAS A. | reporter.nih.gov |
| Prolidase Inhibitors as Therapeutic Agents for Acute Myeloid Leukemia | NIH | National Cancer Institute | 2022 to 2025 | $2,488,178 | March 1, 2022 | February 28, 2027 | BACHOVCHIN, DANIEL | reporter.nih.gov |
| Social Connectedness in Pediatric Brain Cancer Survivors | NIH | National Cancer Institute | 2022 to 2025 | $2,482,532 | January 1, 2022 | June 30, 2027 | HOCKING, MATTHEW C. | reporter.nih.gov |
| Role of lncRNA mediated R-loops in CTCF boundary function and AML genome organization | NIH | National Cancer Institute | 2022 to 2025 | $2,477,191 | December 3, 2021 | November 30, 2026 | HUANG, SUMING | reporter.nih.gov |
| NCI Pediatric In Vivo Testing Program - Leukemia | NIH | National Cancer Institute | 2021 to 2025 | $2,458,093 | August 1, 2015 | June 30, 2026 | LOCK, RICHARD B | reporter.nih.gov |
| MRI-Guided Cryoablation and Imaging-Guided Intratumoral Delivery of STING Agonist Immunotherapy to Target Localized and Metastatic Canine Osteosarcoma | NIH | National Cancer Institute | 2021 to 2024 | $2,454,927 | May 1, 2020 | April 30, 2026 | KRAITCHMAN, DARA L | reporter.nih.gov |
| A “STICK” theranostic nanoplatform for image-guided drug delivery to brain malignancies | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 to 2025 | $2,441,420 | December 18, 2015 | May 31, 2026 | LI, YUANPEI | reporter.nih.gov |
| Machine learning with immunogenetics for the prediction of hematopoietic cell transplant outcomes | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,438,515 | January 5, 2021 | December 31, 2025 | HSU, KATHARINE C | reporter.nih.gov |
| Prodrugs targeting norepinephrine transporter for dual-selective therapy of refractory neuroblastoma | NIH | National Cancer Institute | 2021 to 2024 | $2,435,800 | July 1, 2020 | June 30, 2025 | CHORNY, MICHAEL | reporter.nih.gov |
| Enabling immunotherapy for high-risk Group 3 medulloblastoma via systems immunology | NIH | National Cancer Institute | 2023 to 2025 | $2,416,050 | September 7, 2023 | August 31, 2028 | CHI, HONGBO | reporter.nih.gov |
| DISSECTING THE ROLE OF PRDM15 IN NORMAL HEMATOPOIESIS AND B-CELL MALIGNANCIES | NIH | National Cancer Institute | 2021 to 2025 | $2,407,764 | December 9, 2020 | November 30, 2025 | GUCCIONE, ERNESTO | reporter.nih.gov |
| Liquid biopsy approaches to inform osteosarcoma prognosis and tumor evolution | NIH | National Cancer Institute | 2021 to 2025 | $2,405,560 | July 1, 2025 | June 30, 2027 | CROMPTON, BRIAN | reporter.nih.gov |
| Tumor-Selective Delivery Approaches for Medulloblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $2,405,248 | March 15, 2020 | December 31, 2024 | HELLER, DANIEL ALAN | reporter.nih.gov |
| Targeting FLT3 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | NIH | National Cancer Institute | 2021 to 2025 | $2,401,768 | July 9, 2021 | June 30, 2026 | CALIGIURI, MICHAEL A | reporter.nih.gov |
| The IL-18-IFNγ axis predicts response to immunotherapy | NIH | National Cancer Institute | 2023 to 2025 | $2,399,099 | February 1, 2023 | January 31, 2028 | GUSTAFSON, HEATHER LEIGH HERD | reporter.nih.gov |
| ABERRANT SIGNALING IN ACUTE MYELOID LEUKEMIA | NIH | National Cancer Institute | 2021 to 2025 | $2,398,924 | August 22, 2016 | July 31, 2027 | KENTSIS, ALEX | reporter.nih.gov |
| ROLE OF RNA SEQUESTRATION IN ACUTE MYELOID LEUKEMIA | NIH | National Cancer Institute | 2025 | $2,398,360 | August 15, 2025 | July 31, 2029 | DI STEFANO, BRUNO | reporter.nih.gov |
| STAG2 modulates environmental toxicant exposures and epigenomic heterogeneity | NIH | National Institute of Environmental Health Sciences | 2022 to 2025 | $2,388,852 | March 20, 2022 | December 31, 2026 | OHM, JOYCE ELLEN | reporter.nih.gov |
| Escape from CAR T surveillance through lineage plasticity | NIH | National Cancer Institute | 2022 to 2025 | $2,388,454 | April 1, 2022 | March 31, 2027 | ERNST, PATRICIA | reporter.nih.gov |
| Impact of malaria on shaping immunity to EBV in the etiology of Burkitt lymphoma | NIH | National Cancer Institute | 2021 to 2024 | $2,374,490 | July 10, 2014 | June 30, 2025 | MOORMANN, ANN M | reporter.nih.gov |
| Cytomegalovirus as an etiologic and clinico-pathogenic factor in childhood acute lymphoblastic leukemia | NIH | National Cancer Institute | 2022 to 2025 | $2,371,097 | June 21, 2022 | May 31, 2028 | WIEMELS, JOSEPH LEO | reporter.nih.gov |
| Structural insights into the MLL core complexes | NIH | National Cancer Institute | 2021 to 2024 | $2,368,181 | August 25, 2020 | May 31, 2025 | DOU, YALI | reporter.nih.gov |
| Probing the activity of DUX4 in FSHD | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $2,367,457 | March 19, 2010 | July 31, 2030 | KYBA, MICHAEL | reporter.nih.gov |
| Developing new therapeutic strategies for pediatric tumors that lack clinically actionable mutations | NIH | National Cancer Institute | 2021 to 2025 | $2,360,075 | March 17, 2021 | May 31, 2026 | GEELEHER, PAUL | reporter.nih.gov |
| Targeting integrated metabolic and epigenetic pathways in childhood ependymomas | NIH | National Cancer Institute | 2022 to 2025 | $2,359,774 | July 5, 2022 | June 30, 2027 | VENNETI, SRIRAM | reporter.nih.gov |
| Targeting obesity to improve survival from childhood acute lymphoblastic leukemia | NIH | National Cancer Institute | 2021 to 2025 | $2,359,104 | September 14, 2021 | August 31, 2027 | ORGEL, ETAN | reporter.nih.gov |
| T Cell Regulation of Low-Grade Glioma | NIH | National Cancer Institute | 2022 to 2025 | $2,353,237 | September 9, 2022 | August 31, 2027 | GUTMANN, DAVID H | reporter.nih.gov |
| Development of Advanced Preclinical Models for Pediatric Solid Tumors | NIH | National Cancer Institute | 2021 to 2024 | $2,351,834 | March 5, 2020 | February 28, 2025 | SWEET-CORDERO, ERIC ALEJANDRO | reporter.nih.gov |
| Mechanistic and pharmacologic studies of selective mithramycin analogues targeting EWS-FLI1 in Ewing sarcoma | NIH | National Cancer Institute | 2021 to 2024 | $2,340,398 | June 1, 2020 | May 31, 2026 | TSODIKOV, OLEG V | reporter.nih.gov |
| Developmental Origin, Injury and Epigenomic Regulation of NF1-Associated Peripheral Nerve Sheath Tumors | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $2,339,120 | April 15, 2021 | June 30, 2024 | ZHU, YUAN | reporter.nih.gov |
| Mechanistic Dissection of the BRCA1-SETX-dependent Pathway of R-loop Avoidance and Genome Maintenance | NIH | National Cancer Institute | 2021 to 2025 | $2,336,334 | April 1, 2013 | June 30, 2027 | SUNG, PATRICK | reporter.nih.gov |
| Interrogation of the oxidative-stress-induced leukemia program in vivo using metabolic imaging | NIH | National Cancer Institute | 2023 to 2025 | $2,335,453 | July 1, 2023 | June 30, 2028 | KESHARI, KAYVAN R | reporter.nih.gov |
| Mechanisms whereby IFN-gamma sensitizes AML to the graft-vs-leukemia effect | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,325,780 | April 20, 2021 | March 31, 2026 | SHLOMCHIK, WARREN D | reporter.nih.gov |
| Genomics of childhood acute lymphoblastic leukemia in the Childhood Cancer and Leukemia International Consortium | NIH | National Cancer Institute | 2022 to 2025 | $2,325,747 | August 22, 2022 | July 31, 2027 | SPECTOR, LOGAN G. | reporter.nih.gov |
| Immunotherapeutic targeting of gangliosides in Ewing Sarcoma | NIH | National Cancer Institute | 2023 to 2025 | $2,317,710 | September 19, 2023 | August 31, 2028 | MAJZNER, ROBBIE G. | reporter.nih.gov |
| A personalized approach to skin cancer prevention among adolescents | NIH | National Cancer Institute | 2021 to 2024 | $2,317,171 | March 1, 2020 | February 28, 2026 | WU, YELENA PING | reporter.nih.gov |
| Improving risk allocation and developing novel therapies for children with T-ALL and T-LL | NIH | National Cancer Institute | 2023 to 2025 | $2,310,556 | May 4, 2015 | January 31, 2028 | TEACHEY, DAVID T. | reporter.nih.gov |
| RNA Polymerase II as a Therapeutic Target in Acute Myeloid Leukemia (AML) with RAS Signaling Activation | NIH | National Cancer Institute | 2022 to 2025 | $2,310,466 | July 1, 2022 | June 30, 2027 | SMITH, CATHERINE CHOY | reporter.nih.gov |
| Integrated delivery of cancer control interventions for adolescents and young adults living with HIV in Zambia | NIH | National Cancer Institute | 2023 to 2025 | $2,294,758 | September 1, 2023 | August 31, 2027 | SUBRAMANIAN, SUJHA | reporter.nih.gov |
| Treatment-Related Cardiotoxicity in Children with Relapsed Acute Myeloid Leukemia - Natural History, Occurrence and Implications | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,291,761 | July 15, 2022 | June 30, 2027 | GETZ, KELLY DIRINGER | reporter.nih.gov |
| Uterine signaling networks in the pathogenesis of pulmonary lymphangioleiomyomatosis (LAM) | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $2,284,413 | July 21, 2020 | June 30, 2025 | XU, YAN | reporter.nih.gov |
| THE ROLE OF SELENOPROTEIN SYNTHESIS PATHWAY IN ACUTE MYELOID LEUKEMIA | NIH | National Cancer Institute | 2021 to 2025 | $2,282,168 | July 1, 2021 | June 30, 2027 | NAKADA, DAISUKE | reporter.nih.gov |
| Uncovering treatment targets for peripheral nerve sheath tumor progression in NF1 | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $2,281,119 | September 1, 2020 | June 30, 2025 | LARGAESPADA, DAVID ANDREW | reporter.nih.gov |
| NOURISH-T+: A Randomized Control Trial Targeting Parents in Promoting Healthy Eating and Exercise Behaviors in Pediatric Cancer Survivors with Overweight/Obesity | NIH | National Cancer Institute | 2021 to 2025 | $2,277,684 | December 1, 2019 | November 30, 2026 | STERN, MARILYN | reporter.nih.gov |
| MYCN drives a ferroptotic vulnerability in neuroblastoma | NIH | National Cancer Institute | 2023 to 2025 | $2,275,338 | September 1, 2023 | August 31, 2026 | FABER, ANTHONY CHARLES | reporter.nih.gov |
| The role and therapeutic potential of IGF2BP2 in MLL-rearranged leukemia | NIH | National Cancer Institute | 2022 to 2025 | $2,254,307 | March 1, 2022 | February 28, 2027 | CHEN, JIANJUN | reporter.nih.gov |
| Chronic Health Conditions in Survivors of Down Syndrome-Associated Leukemia | NIH | National Cancer Institute | 2022 to 2025 | $2,251,638 | June 20, 2022 | May 31, 2028 | GRAMATGES, MARIA MONICA | reporter.nih.gov |
| HDO Imaging is a Quantitative Marker of Cerebral Glucose Oxidation | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 to 2025 | $2,249,123 | September 1, 2022 | May 31, 2027 | MERRITT, MATTHEW E | reporter.nih.gov |
| Development of ASH1L inhibitors for acute leukemia | NIH | National Cancer Institute | 2021 to 2024 | $2,243,021 | December 1, 2019 | November 30, 2025 | GREMBECKA, JOLANTA | reporter.nih.gov |
| Targeting FTO to treat acute myeloid leukemia | NIH | National Cancer Institute | 2021 to 2024 | $2,229,526 | December 1, 2019 | November 30, 2025 | CHEN, JIANJUN | reporter.nih.gov |
| PROTECT - Harnessing PROTEin degradation for Advanced Childhood Tumors | NIH | National Cancer Institute | 2024 to 2025 | $2,221,836 | May 1, 2024 | April 30, 2026 | GRAY, NATHANAEL SCHIANDER | reporter.nih.gov |
| Improving genetically engineered T cells for medulloblastomas | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,210,532 | April 15, 2021 | April 30, 2026 | KRENCIUTE, GIEDRE | reporter.nih.gov |
| Gammaherpesvirus miRNA suppression of EWSR1 in GC B cell infection and lymphomagenesis | NIH | National Cancer Institute | 2021 to 2025 | $2,206,513 | August 1, 2021 | July 31, 2026 | TIBBETTS, SCOTT A. | reporter.nih.gov |
| Harnessing the thymus for long-term tumor control with hematopoietic stem cell-derived naive CAR T cells | NIH | National Cancer Institute | 2022 to 2025 | $2,202,507 | March 1, 2022 | January 31, 2027 | ZAKRZEWSKI, JOHANNES | reporter.nih.gov |
| Remodeling of 3D chromatin in B cell acute leukemia and its impact on clinical outcome | NIH | National Cancer Institute | 2021 to 2025 | $2,201,529 | April 1, 2021 | March 31, 2027 | CARROLL, WILLIAM L. | reporter.nih.gov |
| AML mutation-guided drugging of DNA repair | NIH | National Cancer Institute | 2021 to 2024 | $2,200,960 | March 1, 2020 | January 31, 2026 | SKORSKI, TOMASZ | reporter.nih.gov |
| Improving pediatric brain tumor treatments using FLASH radiotherapy | NIH | National Cancer Institute | 2021 to 2025 | $2,200,868 | July 1, 2021 | June 30, 2027 | LIMOLI, CHARLES | reporter.nih.gov |
| Humoral immunity after CAR-T cell therapy for B cell malignancies: The HICAR Study | NIH | National Cancer Institute | 2022 to 2024 | $2,178,209 | January 1, 2020 | December 31, 2025 | HILL, JOSHUA AIDEN | reporter.nih.gov |
| Identification of causal factors underlying cognitive deficits in a mouse model of childhood leukemia survival | NIH | National Institute of Nursing Research | 2021 to 2024 | $2,173,427 | September 7, 2020 | June 30, 2026 | REYES, TERESA M | reporter.nih.gov |
| Targeting an RNA Binding Protein Network in Acute Myeloid Leukemia | NIH | National Cancer Institute | 2021 to 2024 | $2,173,391 | June 1, 2020 | May 31, 2025 | ABDEL-WAHAB, OMAR | reporter.nih.gov |
| Genomically informed agent selection and testing in osteosarcoma patient-derived xenograft models | NIH | National Cancer Institute | 2021 to 2025 | $2,164,771 | July 10, 2015 | June 30, 2026 | GORLICK, RICHARD G. | reporter.nih.gov |
| Skin cancer on social media: Analyzing current communications, modeling diffusion potential, and developing innovative prevention-focused messages | NIH | National Cancer Institute | 2024 to 2025 | $2,164,376 | September 3, 2024 | August 31, 2028 | WALSH-BUHI, ERIC RICHARD | reporter.nih.gov |
| The role of TRIM37 in driving tumorigenesis and cancer-specific vulnerability to PLK4 inhibition | NIH | National Cancer Institute | 2022 to 2025 | $2,153,405 | June 1, 2022 | May 31, 2027 | REGOT, SERGI | reporter.nih.gov |
| Recurrent Tumor-Specific Alternately Processed Transcripts as a Source of Neoantigens for NF1-associated Malignant Peripheral Nerve Sheath Tumor Immunoprevention | NIH | National Cancer Institute | 2021 to 2023 | $2,148,196 | September 25, 2019 | August 31, 2025 | LARGAESPADA, DAVID ANDREW | reporter.nih.gov |
| Re-Engaging AYA Survivors in Cancer-Related Healthcare (REACH): A Sequential Multiple Assignment Randomized Trial (SMART) | NIH | National Cancer Institute | 2023 to 2025 | $2,147,937 | April 21, 2023 | March 31, 2028 | SCHWARTZ, LISA A | reporter.nih.gov |
| Role of PRC1 in RUNX1-ETO-mediated transcriptional control | NIH | National Cancer Institute | 2021 to 2025 | $2,144,475 | July 5, 2021 | December 31, 2026 | HODGES, EMILY | reporter.nih.gov |
| Reprogramming myogenic regulatory factors in RMS to promote differentiation and halt growth | NIH | National Cancer Institute | 2023 to 2025 | $2,136,435 | May 16, 2023 | April 30, 2028 | FORD, HEIDE L. | reporter.nih.gov |
| Patient-Reported Outcomes Version of CTCAE involving Childhood Cancer Survivors | NIH | National Cancer Institute | 2021 to 2023 | $2,133,713 | August 15, 2019 | July 31, 2025 | HUANG, I-CHAN | reporter.nih.gov |
| The Role of miR-142 in the Transformation of Clonal Hematopoietic Disorders into AML | NIH | National Cancer Institute | 2022 to 2025 | $2,133,556 | January 1, 2022 | December 31, 2026 | MARCUCCI, GUIDO | reporter.nih.gov |
| Genomics of AML Prognosis | NIH | National Cancer Institute | 2021 to 2025 | $2,130,312 | April 1, 2008 | June 30, 2027 | LAMBA, JATINDER K. | reporter.nih.gov |
| CAUSAL: Cohort to Augment the Understanding of Sarcoma Survivorship Across the Lifespan | NIH | National Cancer Institute | 2021 to 2022 | $2,127,132 | September 22, 2021 | August 31, 2023 | FRIEDMAN, DEBRA L. | reporter.nih.gov |
| Mechanisms of Toxicity Induced by EWS/FLI1 Overdose in Ewing Sarcoma | NIH | National Cancer Institute | 2023 to 2025 | $2,124,600 | June 7, 2023 | May 31, 2028 | STEGMAIER, KIMBERLY | reporter.nih.gov |
| A novel strategy for transcriptional reprogramming of lymphoid leukemia cells | NIH | National Cancer Institute | 2022 to 2025 | $2,123,519 | January 1, 2022 | December 31, 2026 | CALABRETTA, BRUNO | reporter.nih.gov |
| mRNA stability and its impact on hematopoiesis and acute leukemia | NIH | National Cancer Institute | 2022 to 2025 | $2,122,727 | January 1, 2022 | December 31, 2026 | AIFANTIS, IANNIS | reporter.nih.gov |
| Early Identification of Childhood Cancer Survivors at High Risk for Late Onset Cardiomyopathy: An Artificial Intelligence Approach utilizing Electrocardiography | NIH | National Cancer Institute | 2022 to 2025 | $2,122,194 | April 15, 2022 | March 31, 2027 | AKBILGIC, OGUZ | reporter.nih.gov |
| Elucidating the SCP4 pathway as a multi-catalytic signaling dependency in acute myeloid leukemia | NIH | National Cancer Institute | 2023 to 2025 | $2,121,560 | August 1, 2023 | July 31, 2028 | VAKOC, CHRISTOPHER | reporter.nih.gov |
| Predicting and Monitoring for Cardiac Toxicity in Pediatric AML | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,120,249 | August 25, 2023 | July 31, 2027 | APLENC, RICHARD | reporter.nih.gov |
| Towards rational design of combination therapeutic targets | NIH | National Cancer Institute | 2021 to 2024 | $2,120,092 | June 1, 2020 | May 31, 2025 | TAN, KAI | reporter.nih.gov |
| Quantitative MRI for Pediatric Optic Pathway Glioma Treatment Response | NIH | National Cancer Institute | 2022 to 2024 | $2,119,273 | June 17, 2020 | July 31, 2025 | AVERY, ROBERT ANDREW | reporter.nih.gov |
| Continuous, Non-Invasive Optical Monitoring of Circulating Tumor Cell-Mediated Metastasis in Awake Mice | NIH | National Cancer Institute | 2022 to 2025 | $2,117,767 | March 3, 2022 | February 28, 2027 | NIEDRE, MARK JONATHAN | reporter.nih.gov |
| PolQ as a novel therapeutic target in AML | NIH | National Cancer Institute | 2021 to 2024 | $2,115,741 | January 17, 2020 | December 31, 2025 | SKORSKI, TOMASZ | reporter.nih.gov |
| Myeloid cell-selective, oligonucleotide-based STAT3 inhibition combined with total marrow and lymphoid irradiation for immunotherapy of acute myeloid leukemia | NIH | National Cancer Institute | 2023 to 2025 | $2,114,878 | July 19, 2023 | June 30, 2028 | KORTYLEWSKI, MARCIN | reporter.nih.gov |
| Imaging and manipulating oncoprotein phase separation and compartmentalization | NIH | National Cancer Institute | 2021 to 2025 | $2,110,885 | April 1, 2021 | February 28, 2026 | SHU, XIAOKUN | reporter.nih.gov |
| The function of Snf5 (SMARCB1), an epigenetic tumor suppressor | NIH | National Cancer Institute | 2021 to 2025 | $2,106,784 | July 1, 2005 | March 31, 2026 | ROBERTS, CHARLES | reporter.nih.gov |
| Brain-Imaging Markers of Neurotoxicity and Long-Term Outcomes after CAR-T Cell Therapy | NIH | National Cancer Institute | 2023 to 2025 | $2,106,587 | April 1, 2023 | March 31, 2028 | BANSAL, RAVI | reporter.nih.gov |
| The role of Myeloid cells in pediatric-high grade gliomas | NIH | National Cancer Institute | 2022 to 2025 | $2,100,261 | June 1, 2022 | June 30, 2025 | HAMBARDZUMYAN, DOLORES | reporter.nih.gov |
| Mapping the Cerebellar Origins of Medulloblastoma Subgroups | NIH | National Cancer Institute | 2023 to 2025 | $2,099,734 | February 16, 2023 | January 31, 2028 | NORTHCOTT, PAUL | reporter.nih.gov |
| Translational development of osteosarcoma (OS) extracellular vesicle (EV) matrix metalloproteinase (MMP) Activity Assay for assessing patient treatment responses | NIH | National Cancer Institute | 2025 | $2,097,875 | September 1, 2025 | August 31, 2029 | TSENG, HSIAN-RONG | reporter.nih.gov |
| Ink4a/ARF/Ink4b locus in Neurofibromatosis Type 1 | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $2,097,360 | March 1, 2022 | February 28, 2027 | DODD, REBECCA D | reporter.nih.gov |
| Inhibition of Bcl-xL by Targeted Degradation | NIH | National Cancer Institute | 2021 to 2024 | $2,097,141 | April 1, 2020 | March 31, 2026 | ZHENG, GUANGRONG | reporter.nih.gov |
| Production and progression of premalignant retinoblastoma lesions. | NIH | National Cancer Institute | 2021 to 2025 | $2,094,221 | March 1, 2011 | July 31, 2029 | COBRINIK, DAVID | reporter.nih.gov |
| Small molecule mimetics of Humanin that normalize neuronal p-Akt as novel therapeutics for AD | NIH | National Institute on Aging | 2021 to 2023 | $2,091,868 | April 1, 2021 | March 31, 2024 | JOHN, VARGHESE | reporter.nih.gov |
| Novel combination therapy for AML expressing mutant RUNX1 | NIH | National Cancer Institute | 2021 to 2024 | $2,088,671 | September 1, 2021 | August 31, 2025 | DINARDO, COURTNEY | reporter.nih.gov |
| Defining the Mechanism of Genome Rearrangements in Ph-Like ALL to Determine Predictive Markers in High-Risk Hispanic Populations | NIH | National Cancer Institute | 2022 to 2025 | $2,085,711 | February 14, 2022 | January 31, 2027 | PANNUNZIO, NICHOLAS | reporter.nih.gov |
| Early clinical development of a novel IL-7R antibody for treating children with relapsed T-cell leukemia | NIH | National Cancer Institute | 2022 to 2025 | $2,084,309 | April 1, 2022 | August 31, 2026 | VARADHACHARY, ATUL | reporter.nih.gov |
| Advancing allogeneic CAR-iNKT for the treatment of solid tumors through comparative oncology | NIH | National Cancer Institute | 2022 to 2025 | $2,083,891 | September 1, 2022 | August 31, 2027 | MASON, NICOLA J | reporter.nih.gov |
| Mechanisms and Vulnerabilities of Aberrant Transcriptional Enhancers in Cancer | NIH | National Cancer Institute | 2021 to 2022 | $2,071,954 | September 1, 2016 | August 31, 2023 | LOOK, A. THOMAS | reporter.nih.gov |
| Integrating Transforming Approaches to Identify and Target New Vulnerabilities in Cancer | NIH | National Cancer Institute | 2021 to 2022 | $2,071,953 | August 9, 2016 | July 31, 2023 | STEGMAIER, KIMBERLY | reporter.nih.gov |
| EPIGENETIC REPROGRAMMING OF T CELL EXHAUSTION TO ENHANCE TUMOR IMMUNOTHERAPY | NIH | National Cancer Institute | 2021 to 2025 | $2,070,977 | March 1, 2020 | March 31, 2030 | YOUNGBLOOD, BENJAMIN ALAN | reporter.nih.gov |
| Role of FACT in ZFTA-RelA fusion driven ependymoma | NIH | National Cancer Institute | 2023 to 2025 | $2,070,282 | April 1, 2023 | March 31, 2028 | VENERE, MONICA | reporter.nih.gov |
| New control of oncogene activation in T-cell leukemia | NIH | National Cancer Institute | 2022 to 2025 | $2,064,320 | April 12, 2022 | March 31, 2027 | LIANG, CHENGYU | reporter.nih.gov |
| Mechanisms of resistance to ALK inhibitors in ALK-rearranged lymphoma | NIH | National Cancer Institute | 2021 to 2025 | $2,064,042 | July 16, 2015 | November 30, 2026 | CHIARLE, ROBERTO | reporter.nih.gov |
| A Biobehavioral Intervention to Reduce Adverse Outcomes in Young Adult Testicular Cancer Survivors | NIH | National Cancer Institute | 2023 to 2025 | $2,056,218 | July 8, 2023 | June 30, 2028 | HOYT, MICHAEL A | reporter.nih.gov |
| Identifying markers of abnormal neurocognitive trajectories during chemotherapy treatment of childhood acute lymphoblastic leukemia | NIH | National Cancer Institute | 2022 to 2025 | $2,055,804 | September 1, 2022 | August 31, 2027 | VAN DER PLAS, ELLEN | reporter.nih.gov |
| Dissecting and Targeting RB1-Mutant Osteosarcoma | NIH | National Cancer Institute | 2021 to 2025 | $2,054,629 | March 1, 2021 | February 28, 2027 | LEE, DUNG-FANG | reporter.nih.gov |
| Targeting tumor and T cell DNA methylomes to improve CAR T cell therapies for diffuse midline glioma | NIH | National Cancer Institute | 2023 to 2025 | $2,052,826 | September 7, 2023 | August 31, 2028 | MACK, STEPHEN C | reporter.nih.gov |
| Novel CART Cells for Treating AML | NIH | National Cancer Institute | 2022 to 2025 | $2,049,319 | June 1, 2022 | May 31, 2027 | HUA, XIANXIN | reporter.nih.gov |
| Map Leukemia-immune Cell Talks with Nanoplasmon Ruler in CAR T-Cell Immunotherapy | NIH | National Cancer Institute | 2021 to 2024 | $2,039,396 | July 1, 2020 | June 30, 2025 | CHEN, WEIQIANG | reporter.nih.gov |
| Spatial Control of Myeloid Differentiation | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,038,767 | August 15, 2021 | December 31, 2024 | LUCAS, DANIEL | reporter.nih.gov |
| Isabl GxT: A clinically actionable whole genome and transcriptome precision medicine platform | NIH | National Cancer Institute | 2023 to 2024 | $2,033,377 | April 1, 2023 | March 31, 2026 | MEDINA, JUAN SANTIAGO | reporter.nih.gov |
| Characterizing the MSI2 network in leukemia | NIH | National Cancer Institute | 2021 to 2025 | $2,029,035 | April 1, 2015 | November 30, 2025 | KHARAS, MICHAEL | reporter.nih.gov |
| Survivorship and Access to care for Latinos to Understand and address Disparities (SALUD) | NIH | National Cancer Institute | 2021 to 2022 | $2,026,200 | May 10, 2021 | April 30, 2023 | SCHEURER, MICHAEL E. | reporter.nih.gov |
| Mechanisms of differentiation blockade in CSF3R-mutant AML | NIH | National Cancer Institute | 2021 to 2025 | $2,023,612 | February 5, 2021 | January 31, 2027 | MAXSON, JULIA E | reporter.nih.gov |
| Investigating the IL-1R Pathway in Anaplastic Large Cell Lymphoma for Targeted Therapy | NIH | National Cancer Institute | 2021 to 2025 | $2,022,453 | April 6, 2021 | March 31, 2027 | YANG, YIBIN | reporter.nih.gov |
| TET2-mediated epitranscriptomic regulation in leukemia microenvironment | NIH | National Cancer Institute | 2023 to 2025 | $2,018,981 | September 21, 2023 | August 31, 2028 | CHEN, JIANJUN | reporter.nih.gov |
| Mediators Of Arrested Differentiation In Pediatric Rhabdomyosarcoma | NIH | National Cancer Institute | 2021 to 2025 | $2,016,077 | February 1, 2021 | January 31, 2027 | HATLEY, MARK EDWARD | reporter.nih.gov |
| Targeted Small Molecule Inhibitors for Inv(16) Leukemia | NIH | National Cancer Institute | 2021 to 2023 | $2,012,862 | December 1, 2018 | November 30, 2024 | BUSHWELLER, JOHN HACKETT | reporter.nih.gov |
| Uncover the role of H3.3-G343R mutation in shaping the DNA damage response, anti-tumor immunity and mechanisms of resistance in glioma. | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $2,006,629 | January 15, 2022 | December 31, 2026 | CASTRO, MARIA G | reporter.nih.gov |
| Central tolerance mechanisms in B-cell malignancies | NIH | National Cancer Institute | 2021 to 2025 | $2,003,674 | June 1, 2011 | June 30, 2027 | MÜSCHEN, MARKUS | reporter.nih.gov |
| Explore the signaling mechanisms of acquired resistance to tyrosine kinase inhibitors in AML | NIH | National Cancer Institute | 2021 to 2025 | $2,002,562 | March 3, 2021 | February 28, 2026 | HUANG, JIAN | reporter.nih.gov |
| Matching panels of in vivo and in vitro model system of pediatric brain tumors | NIH | National Cancer Institute | 2021 to 2024 | $2,001,657 | March 3, 2020 | February 28, 2026 | LI, XIAONAN | reporter.nih.gov |
| Investigating the role of KAT6A in MLL-rearranged acute myeloid leukemia | NIH | National Cancer Institute | 2022 to 2025 | $2,001,625 | September 1, 2022 | August 31, 2027 | BLANCO, MARIO ANDRES | reporter.nih.gov |
| Role of HOTTIP/beta-catenin-HOXA9/PRMT1 axis in hematopoietic and leukemic stem cells | NIH | National Cancer Institute | 2022 to 2025 | $2,000,732 | July 1, 2022 | June 30, 2027 | HUANG, SUMING | reporter.nih.gov |
| Evaluation of the safety and efficacy of non-invasive sonodynamic therapy for diffuse intrinsic pontine glioma | NIH | National Cancer Institute | 2022 to 2023 | $2,000,000 | May 1, 2022 | August 31, 2024 | MARCUS, STUART | reporter.nih.gov |
| AI-based AML risk stratification using next generation cytogenomics | NIH | National Cancer Institute | 2023 to 2024 | $2,000,000 | July 1, 2023 | June 30, 2025 | EACKER, STEPHEN MATTHEW | reporter.nih.gov |
| Simultaneous pharmacological profiling of oncogenic gene fusion proteins in cancer | NIH | National Cancer Institute | 2023 to 2024 | $2,000,000 | July 1, 2023 | June 30, 2025 | FEDERATION, ALEXANDER | reporter.nih.gov |
| A Phase 1b, Open-Label, Study of a Novel Targeted Radiotherapy in Children, Adolescents and Young Adults with Inoperable Relapsed or Refractory High Grade Glioma | NIH | National Cancer Institute | 2022 to 2023 | $1,999,998 | September 16, 2022 | June 30, 2024 | REILLY, LAURENCE | reporter.nih.gov |
| TOPIC 414 : SYNTHETIC BIOLOGY GENE CIRCUITS FOR CANCER THERAPY | NIH | National Cancer Institute | 2021 | $1,999,993 | August 1, 2021 | July 31, 2023 | LEE, GARY | reporter.nih.gov |
| Dual-targeting allogeneic CAR T-cells for universal therapy of T-cell malignancies | NIH | National Cancer Institute | 2024 to 2025 | $1,999,703 | September 1, 2024 | August 31, 2027 | HEIN, SARAH MARIE | reporter.nih.gov |
| GENETICALLY ENGINEERED T CELLS FOR DIPG | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,999,395 | August 1, 2022 | July 31, 2027 | KRENCIUTE, GIEDRE | reporter.nih.gov |
| Ceraxa (Ceramide NanoLiposome) and Vinblastine For the Improved Treatment of Relapsed or Refractory Acute Myeloid Leukemia | NIH | National Cancer Institute | 2022 to 2023 | $1,999,256 | September 14, 2022 | August 31, 2025 | ADAIR, BERNADETTE MCMAHON | reporter.nih.gov |
| Vascular Remodeling in the Bone Marrow Leukemic Niche: A Therapeutic Target? | NIH | National Cancer Institute | 2021 to 2024 | $1,996,349 | April 1, 2020 | March 31, 2026 | MARCUCCI, GUIDO | reporter.nih.gov |
| Transporters and Medulloblastoma | NIH | National Cancer Institute | 2021 to 2025 | $1,995,922 | April 1, 2015 | November 30, 2026 | SCHUETZ, JOHN D | reporter.nih.gov |
| Integrated Systems Biology of Pediatric AML | NIH | National Cancer Institute | 2023 to 2025 | $1,995,809 | December 15, 2022 | November 30, 2027 | LAMBA, JATINDER K. | reporter.nih.gov |
| Phase 2 clinical trial of a novel T cell therapy following bridging therapy with hypomethylating agents for relapsed AML patients post-stem cell transplant | NIH | National Cancer Institute | 2023 to 2025 | $1,994,514 | August 10, 2023 | July 31, 2026 | VERA, JUAN FERNANDO | reporter.nih.gov |
| Engineering an immuno-isolating hydrogel for restoring ovarian endocrine function | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $1,991,992 | September 30, 2016 | February 28, 2026 | SHIKANOV, ARIELLA | reporter.nih.gov |
| Biomarkers of Vision Loss in Children with Optic Pathway Gliomas | NIH | National Eye Institute | 2021 to 2023 | $1,991,559 | March 1, 2019 | February 28, 2025 | AVERY, ROBERT ANDREW | reporter.nih.gov |
| Multisite Implementation of COMPRENDO (ChildhOod Malignancy Peer REsearch NavigatiOn) to improve participation of Hispanic children in cancer clinical trials | NIH | National Cancer Institute | 2023 to 2025 | $1,990,997 | July 26, 2023 | June 30, 2028 | ARISTIZABAL, PAULA | reporter.nih.gov |
| Development of an immunomodulating peptide as a therapy for osteosarcoma in canine and human | NIH | National Cancer Institute | 2023 to 2024 | $1,990,199 | September 19, 2023 | August 31, 2025 | ALFARO, JOSHUA | reporter.nih.gov |
| Targeting vulnerabilities of PPM1D-mutant gliomas | NIH | National Cancer Institute | 2021 to 2025 | $1,989,782 | February 1, 2021 | January 31, 2026 | BANDOPADHAYAY, PRATITI | reporter.nih.gov |
| Novel Therapeutic Approaches for the Treatment of Neuroblastoma | NIH | National Cancer Institute | 2021 to 2024 | $1,988,123 | April 1, 2020 | March 31, 2026 | DYER, MICHAEL A | reporter.nih.gov |
| The role of the cohesin complex in hematopoietic transformation and leukemia maintenance | NIH | National Cancer Institute | 2023 to 2025 | $1,987,941 | September 19, 2023 | August 31, 2028 | VINY, AARON D | reporter.nih.gov |
| Identification of Novel Pathways Causing NF1-Driven Schwann Cell Tumors | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,987,528 | December 1, 2021 | November 30, 2026 | RATNER, NANCY | reporter.nih.gov |
| Mechanisms and targeting of aberrant Gas activation in myeloid neoplasms | NIH | National Cancer Institute | 2023 to 2025 | $1,986,303 | April 1, 2023 | March 31, 2028 | PAPAPETROU, EIRINI | reporter.nih.gov |
| Digital Self-Management and Peer Mentoring Intervention to Improve the Transition from Pediatric to Adult Health Care for Childhood Cancer Survivors | NIH | National Cancer Institute | 2023 to 2025 | $1,984,223 | July 1, 2023 | June 30, 2028 | DEVINE, KATIE A | reporter.nih.gov |
| Targeting Syk to enhance anti-tumor immune responses in neuroblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,981,973 | August 1, 2021 | April 30, 2026 | JOSHI, SHWETA | reporter.nih.gov |
| Defining epigenetic mechanisms in NPM1c mutant leukemia | NIH | National Cancer Institute | 2021 to 2025 | $1,981,710 | April 9, 2021 | March 31, 2027 | ARMSTRONG, SCOTT A | reporter.nih.gov |
| AF9(MLLT3) Function in Leukemia and Normal Hematopoiesis | NIH | National Cancer Institute | 2021 to 2023 | $1,980,668 | July 1, 2019 | June 30, 2025 | BUSHWELLER, JOHN HACKETT | reporter.nih.gov |
| Delirium in Children Undergoing Hematopoietic Stem Cell Transplants | NIH | National Cancer Institute | 2021 to 2024 | $1,975,976 | September 1, 2020 | May 31, 2026 | TRAUBE, CHANI | reporter.nih.gov |
| Measuring Perceptions of Utility of Clinical Genome Sequencing: Instrument Testing and Validation | NIH | National Human Genome Research Institute | 2021 | $1,974,475 | December 5, 2011 | May 31, 2023 | PLON, SHARON E. | reporter.nih.gov |
| Mechanistic biomarkers to enable Bcl2 inhibitor therapies for neuroblastoma | NIH | National Cancer Institute | 2021 to 2025 | $1,974,115 | February 18, 2021 | January 31, 2026 | HOGARTY, MICHAEL D | reporter.nih.gov |
| Elucidating the role of the noncoding genome in neuroblastoma | NIH | National Cancer Institute | 2021 to 2025 | $1,973,426 | March 12, 2021 | February 28, 2027 | DISKIN, SHARON | reporter.nih.gov |
| A novel approach for treating myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) | NIH | National Cancer Institute | 2024 to 2025 | $1,972,824 | September 9, 2024 | August 31, 2026 | FAN, XIAOMIN | reporter.nih.gov |
| Bioethics research to understand engagement in decision-making among adolescents and young adults with cancer at risk for health care disparities | NIH | National Cancer Institute | 2023 to 2025 | $1,967,607 | September 1, 2025 | August 31, 2026 | MACK, JENNIFER W | reporter.nih.gov |
| Towards an inclusive genomic risk classification for acute myeloid leukemia (AML) | NIH | National Cancer Institute | 2023 to 2025 | $1,961,587 | September 18, 2023 | July 31, 2028 | EISFELD, ANN-KATHRIN | reporter.nih.gov |
| End-of-life care quality for adolescents and young adults with cancer: Including the patient voice in quality assessment | NIH | National Cancer Institute | 2021 to 2025 | $1,960,563 | February 13, 2018 | December 31, 2029 | MACK, JENNIFER W | reporter.nih.gov |
| Toward Translation of an Immunotherapeutic Nanomedicine for Neuroblastoma | NIH | National Cancer Institute | 2022 to 2025 | $1,952,176 | July 1, 2022 | June 30, 2027 | WILSON, JOHN TANNER | reporter.nih.gov |
| Image-guided dosimetry-based alpha particle therapy for neuroblastoma. | NIH | National Cancer Institute | 2022 to 2023 | $1,951,675 | August 4, 2022 | July 31, 2025 | SCHULTZ, MICHAEL KING | reporter.nih.gov |
| Overcoming Resistance Mechanisms in Hedgehog and Myc-amplified Medulloblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,949,505 | December 1, 2020 | November 30, 2025 | MAHATO, RAM I. | reporter.nih.gov |
| First-in-class ETS inhibitor TK216: Translational Biology and Oral Dosage Form Development | NIH | National Cancer Institute | 2021 to 2022 | $1,948,791 | September 1, 2021 | August 31, 2024 | KRISHNAN, RAJESH | reporter.nih.gov |
| Modulating the PD-1/PD-L1 checkpoint to promote antitumor activity of HER2 CAR T cells in patients with sarcoma | NIH | National Cancer Institute | 2023 to 2025 | $1,938,900 | March 7, 2023 | February 29, 2028 | HEGDE, MEENAKSHI G | reporter.nih.gov |
| The role of ATRX mutation in the epigenetic dysregulation of cell cycle in pediatric high-grade glioma | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,938,300 | July 1, 2021 | June 30, 2026 | KOSCHMANN, CARL J | reporter.nih.gov |
| A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors | NIH | National Cancer Institute | 2021 to 2023 | $1,926,339 | September 19, 2019 | August 31, 2025 | KADAN-LOTTICK, NINA S | reporter.nih.gov |
| Engineering 3D Osteosarcoma Models to Elucidate Biology and Inform Drug Discovery | NIH | National Cancer Institute | 2023 to 2025 | $1,924,041 | April 1, 2023 | March 31, 2028 | YANG, FAN | reporter.nih.gov |
| Therapeutic degradation of Capicua (CIC) fused oncoproteins in undifferentiated sarcomas | NIH | National Cancer Institute | 2021 to 2025 | $1,922,391 | June 17, 2021 | May 31, 2026 | OKIMOTO, ROSS | reporter.nih.gov |
| Derivation of Functional Spermatogonia Stem Cells from Rhesus Macaque iPSCs | NIH | Office of the Director, National Institutes of Health | 2021 to 2022 | $1,921,633 | September 9, 2019 | June 30, 2024 | EASLEY, CHARLES A. | reporter.nih.gov |
| Large scale single-cell gene rearrangement detection with a microfluidic device | NIH | National Cancer Institute | 2021 to 2025 | $1,921,615 | July 1, 2020 | June 30, 2027 | ZHONG, JOHN | reporter.nih.gov |
| Preclinical-Clinical Trials Collaboration to effectively advance new combination therapies for malignant peripheral nerve sheath tumors | NIH | National Cancer Institute | 2022 to 2025 | $1,921,213 | July 8, 2022 | June 30, 2027 | CICHOWSKI, KAREN M | reporter.nih.gov |
| Therapeutic strategies for treatment of giant congenital melanocytic nevi | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $1,921,106 | August 1, 2017 | July 31, 2028 | FISHER, DAVID E | reporter.nih.gov |
| Bright IDEAS-Young Adults: Problem-Solving Skills Training to Reduce Distress among Young Adults with Cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,919,850 | April 15, 2020 | March 31, 2027 | DEVINE, KATIE A | reporter.nih.gov |
| Improving Patient-Important Outcomes with Testosterone Replacement in Hypogonadal Men with a Prior History of Cancer | NIH | National Cancer Institute | 2022 to 2025 | $1,917,613 | May 8, 2019 | April 30, 2027 | GARCIA, JOSE M. | reporter.nih.gov |
| Investigation of ecDNA as a driver of intratumoral heterogeneity and treatment resistance in high-risk medulloblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,914,963 | September 1, 2023 | August 31, 2028 | CHAVEZ, LUKAS | reporter.nih.gov |
| HPV, HIV and Oral Microbiota Interplay in Nigerian Youth (HOMINY) | NIH | National Institute of Dental & Craniofacial Research | 2024 to 2025 | $1,910,616 | August 1, 2024 | July 31, 2027 | COKER, MODUPE | reporter.nih.gov |
| Mechanism of Therapy in high-risk AML | NIH | National Cancer Institute | 2021 to 2024 | $1,909,701 | July 1, 2020 | June 30, 2025 | AZAM, MOHAMMAD | reporter.nih.gov |
| MICROFABRICATED INSTRUMENTATION TO MEASURE SPHINGOLIPID SIGNALING IN HUMAN ACUTE MYELOID LEUKEMIA | NIH | National Cancer Institute | 2021 to 2023 | $1,909,270 | May 7, 2019 | April 30, 2025 | ALLBRITTON, NANCY L. | reporter.nih.gov |
| Exposure to per- and polyfluoroalkyl substances (PFAS) and risk of cancer in children | NIH | National Institute of Environmental Health Sciences | 2021 to 2023 | $1,909,233 | September 3, 2021 | August 31, 2025 | METAYER, CATHERINE | reporter.nih.gov |
| The Role of HIF1A-DNMT3A axis in AML1/ETO-Driven Acute MyelogenousLeukemia | NIH | National Cancer Institute | 2023 to 2025 | $1,908,225 | December 7, 2020 | November 30, 2026 | LIU, SHUJUN | reporter.nih.gov |
| Evaluating environmental metals exposure on risk of LCH | NIH | National Cancer Institute | 2021 to 2023 | $1,903,519 | August 1, 2019 | July 31, 2025 | SCHEURER, MICHAEL E. | reporter.nih.gov |
| Lipid nanomedicine targeting multiple signaling pathways of medulloblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,901,424 | July 15, 2022 | May 31, 2027 | MAHATO, RAM I. | reporter.nih.gov |
| Project Milestones: Young Adult Cancer Survivorship | NIH | National Cancer Institute | 2021 to 2024 | $1,898,106 | May 4, 2021 | December 31, 2025 | MILAM, JOEL E | reporter.nih.gov |
| Regulation of FLT3 Signaling in Leukemia | NIH | National Cancer Institute | 2023 to 2025 | $1,897,988 | September 1, 2023 | August 31, 2028 | TONG, WEI | reporter.nih.gov |
| The role of DNAJB1-PKAc-β-catenin axis in fibrolamellar HCC | NIH | National Cancer Institute | 2023 to 2025 | $1,896,102 | April 1, 2023 | March 31, 2028 | TIMCHENKO, NIKOLAI A. | reporter.nih.gov |
| Mdm2 Alternative Splicing in DNA Damage and Cancer | NIH | National Cancer Institute | 2021 to 2024 | $1,893,675 | September 1, 2021 | August 31, 2026 | CHANDLER, DAWN S | reporter.nih.gov |
| Using Tailored mHealth Strategies to Promote Weight Management among Adolescent and Young Adult Cancer Survivors | NIH | National Cancer Institute | 2023 to 2025 | $1,883,659 | April 1, 2023 | March 31, 2028 | VALLE, CARMINA G | reporter.nih.gov |
| A Systems Epidemiology Approach for Predicting Methotrexate Neurotoxicity in Pediatric Acute Leukemia | NIH | National Cancer Institute | 2023 to 2025 | $1,882,395 | April 21, 2023 | March 31, 2028 | BROWN, AUSTIN L | reporter.nih.gov |
| Developmental regulation of apoptosis as a modifiable driver of radiotherapy-induced neurocognitive impairment in pediatric patients | NIH | National Cancer Institute | 2021 to 2025 | $1,878,585 | March 9, 2020 | February 28, 2027 | SAROSIEK, KRISTOPHER ANDREW | reporter.nih.gov |
| Transcriptional Regulation in ZFTA-RELA Ependymoma | NIH | National Cancer Institute | 2023 to 2025 | $1,877,375 | August 1, 2023 | July 31, 2028 | MACK, STEPHEN C | reporter.nih.gov |
| Targeting Menin in Acute Leukemia with Upregulated HOX Genes | NIH | National Cancer Institute | 2023 to 2025 | $1,868,714 | May 1, 2023 | April 30, 2028 | GREMBECKA, JOLANTA | reporter.nih.gov |
| Research Training in Pediatric Oncology | NIH | National Cancer Institute | 2021 to 2024 | $1,864,901 | July 13, 2009 | June 30, 2025 | ARMSTRONG, SCOTT A | reporter.nih.gov |
| Targeting cooperative mechanisms of metastatic colonization in osteosarcoma | NIH | National Cancer Institute | 2022 to 2025 | $1,864,638 | July 6, 2022 | June 30, 2027 | ROBERTS, RYAN D. | reporter.nih.gov |
| Next Generation Immunotherapies for Pediatric Cancers | NIH | National Cancer Institute | 2024 to 2025 | $1,863,847 | September 9, 2024 | August 31, 2031 | MACKALL, CRYSTAL | reporter.nih.gov |
| 3-Dimensional Retinal Organoid Platform for the Study of Retinoblastoma | NIH | National Cancer Institute | 2021 to 2024 | $1,863,510 | September 15, 2020 | June 30, 2025 | PELAEZ, DANIEL | reporter.nih.gov |
| Exercise as an Immune Adjuvant for Gamma Delta T-cell Therapies in Hematologic Malignancies | NIH | National Cancer Institute | 2023 to 2025 | $1,860,326 | April 1, 2023 | March 31, 2028 | SIMPSON, RICHARD J | reporter.nih.gov |
| Transcription factors in kidney development | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $1,856,383 | August 15, 2003 | December 31, 2027 | XU, PIN-XIAN | reporter.nih.gov |
| Tumor 'tractor beam' for diffuse cancers | NIH | National Cancer Institute | 2021 to 2025 | $1,854,880 | September 23, 2021 | August 31, 2026 | MOKARRAM-DORRI, NASSIR | reporter.nih.gov |
| Mechanisms and small-molecule targeting of SWI/SNF activity in neuroblastoma | NIH | National Cancer Institute | 2022 to 2025 | $1,853,581 | July 18, 2022 | June 30, 2027 | HODGES, HAMILTON COURTNEY | reporter.nih.gov |
| Molecular Mechanism of Leukemogenesis involving AML1-ETO | NIH | National Cancer Institute | 2021 to 2025 | $1,849,687 | July 16, 2004 | March 31, 2027 | ZHANG, DONG-ER | reporter.nih.gov |
| SMARCB1 regulated SWI/SNF complex function in Malignant Rhabdoid Tumors | NIH | National Cancer Institute | 2021 to 2025 | $1,849,490 | April 1, 2021 | March 31, 2027 | WANG, XIAOFENG | reporter.nih.gov |
| Modeling BRAF-fusion driven pediatric brain tumors in the mouse | NIH | National Cancer Institute | 2021 to 2023 | $1,848,656 | June 1, 2019 | May 31, 2024 | VENTURA, ANDREA | reporter.nih.gov |
| Evaluation of a telehealth oncofertility care intervention in adolescent and young adult cancer patients: a stepped wedge cluster randomized controlled trial | NIH | National Cancer Institute | 2023 to 2025 | $1,843,991 | December 1, 2022 | November 30, 2027 | SU, HUI-CHUN IRENE | reporter.nih.gov |
| An Integrative Approach to Evaluate Neurocognitive Disparities in Latinos Undergoing Treatment for Childhood Leukemia. | NIH | National Cancer Institute | 2022 to 2025 | $1,843,835 | July 1, 2022 | June 30, 2028 | RAGHUBAR, KIMBERLY PAULINE | reporter.nih.gov |
| Targeting PRC1 in leukemia | NIH | National Cancer Institute | 2023 to 2025 | $1,843,693 | September 1, 2023 | August 31, 2028 | CIERPICKI, TOMASZ | reporter.nih.gov |
| Measuring Lifelong Multimorbidity with Patient Perspectives: Implementing and Visualizing the Cumulative Burden Methodology Across Cohorts | NIH | National Cancer Institute | 2022 to 2025 | $1,843,355 | March 11, 2022 | February 28, 2026 | BHAKTA, NICKHILL HITESH | reporter.nih.gov |
| Robust assays to define telomere maintenance mechanisms as cancer biomarkers. | NIH | National Cancer Institute | 2021 to 2025 | $1,833,412 | September 16, 2021 | August 31, 2027 | REYNOLDS, CHARLES PATRICK | reporter.nih.gov |
| CAR NKT Cell Immunotherapy of Neuroblastoma | NIH | National Cancer Institute | 2021 to 2025 | $1,828,377 | June 12, 2021 | May 31, 2026 | METELITSA, LEONID S | reporter.nih.gov |
| An augmented reality platform to reduce post-operative and chronic opioid use in pediatric cancer | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,828,326 | June 1, 2020 | August 31, 2024 | YORK, CHRISTINA | reporter.nih.gov |
| Attacking the Immunopeptidome of Ewing Sarcoma | NIH | National Cancer Institute | 2023 to 2025 | $1,827,865 | September 11, 2023 | July 31, 2028 | MACKALL, CRYSTAL | reporter.nih.gov |
| Phase 0/1 trial of ONC206 - a novel imipridone for children with diffuse midline gliomas and recurrent malignant brain tumors | NIH | National Cancer Institute | 2022 to 2025 | $1,826,791 | September 7, 2022 | August 31, 2028 | MUELLER, SABINE | reporter.nih.gov |
| Research Training in Childhood Cancer | NIH | National Cancer Institute | 2021 to 2025 | $1,823,127 | July 1, 2007 | August 31, 2027 | SWEET-CORDERO, ERIC ALEJANDRO | reporter.nih.gov |
| Development of a generalizable chemo-proteomics screening platform for small molecule degraders applied to HDACs | NIH | National Cancer Institute | 2022 to 2025 | $1,822,992 | June 7, 2022 | April 30, 2026 | FISCHER, ERIC SEBASTIAN | reporter.nih.gov |
| A Randomized Controlled Trial using a Heuristic Tool To Improve Symptom Self-Management in Adolescents and Young Adults with Cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,822,032 | June 9, 2023 | May 31, 2027 | ELSWICK, RONALD K. | reporter.nih.gov |
| Tumor-derived extracellular vesicles in the pre-metastatic niche. | NIH | National Cancer Institute | 2021 to 2025 | $1,821,912 | August 1, 2017 | August 31, 2029 | DECLERCK, YVES A | reporter.nih.gov |
| Evaluating ADGRB3 as a tumor suppressor epigenetically silenced in WNT medulloblastoma | NIH | National Cancer Institute | 2021 to 2024 | $1,815,797 | September 1, 2019 | January 31, 2025 | VAN MEIR, ERWIN G. | reporter.nih.gov |
| METABOLIC REGULATION IN LEUKEMIA-INITIATING CELLS | NIH | National Cancer Institute | 2021 to 2024 | $1,806,031 | April 1, 2015 | June 30, 2025 | NAKADA, DAISUKE | reporter.nih.gov |
| An Integrated Biochemical and Structural Approach to Delineating the Biology of EWSR1 | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $1,805,092 | September 30, 2021 | June 30, 2026 | LIBICH, DAVID STEVEN | reporter.nih.gov |
| Analysis of E-selectin Ligands of Human Acute Leukemia Cells and their Biology in Leukemogenesis | NIH | National Cancer Institute | 2021 to 2023 | $1,799,538 | July 17, 2019 | June 30, 2025 | SACKSTEIN, ROBERT | reporter.nih.gov |
| Symptom Screening Linked to Care Pathways for Children with Cancer: a Cluster Randomized Trial | NIH | National Cancer Institute | 2021 to 2024 | $1,797,779 | August 1, 2020 | April 30, 2025 | SUNG, LILLIAN | reporter.nih.gov |
| Trispecific CAR-T cells targeting CD19, CD20 and CD22 to treat B-cell malignancies | NIH | National Cancer Institute | 2023 to 2025 | $1,797,355 | July 21, 2023 | June 30, 2028 | VASU, SUMITHIRA | reporter.nih.gov |
| Targeting GSK3B in refractory B-cell malignancies | NIH | National Cancer Institute | 2023 to 2025 | $1,794,818 | July 19, 2023 | June 30, 2028 | MÜSCHEN, MARKUS | reporter.nih.gov |
| VLA-4–targeted 67Cu-LLP2A preconditioning enhances efficacy of T-cell-based adoptive immunotherapy | NIH | National Cancer Institute | 2023 to 2025 | $1,788,311 | July 5, 2023 | June 30, 2028 | PATEL, RAVI BHASKER | reporter.nih.gov |
| Cause and therapeutic impact of DNA-protein crosslink repair defect in myeloid leukemias | NIH | National Cancer Institute | 2021 to 2025 | $1,785,830 | July 1, 2021 | June 30, 2026 | KAUFMANN, SCOTT H | reporter.nih.gov |
| Evaluation of the Communication Plan Early through End-of-Life (COMPLETE) Intervention | NIH | National Cancer Institute | 2021 to 2024 | $1,785,128 | August 13, 2019 | July 31, 2025 | PERKINS, SUSAN M. | reporter.nih.gov |
| Ameliorating off-target toxicities of CAR T cells by engineering NOT gates | NIH | National Cancer Institute | 2022 to 2025 | $1,777,692 | August 1, 2022 | July 31, 2027 | LIM, WENDELL A | reporter.nih.gov |
| NextGen - CHOP | NIH | National Cancer Institute | 2022 to 2025 | $1,775,451 | June 1, 2025 | May 31, 2026 | MARIS, JOHN M | reporter.nih.gov |
| Leveraging the TCR Repertoire to identify target neoantigens in FLT3-ITD positive Acute Myeloid Leukemia | NIH | National Cancer Institute | 2021 to 2025 | $1,769,974 | June 1, 2021 | May 31, 2027 | ALACHKAR, HOUDA | reporter.nih.gov |
| Molecular Pathogenesis of AF10-Rearranged Leukemias | NIH | National Cancer Institute | 2022 to 2025 | $1,767,803 | April 12, 2022 | March 31, 2027 | DESHPANDE, ANIRUDDHA J. | reporter.nih.gov |
| Oncogenic Drivers of Rhabdomyosarcoma Cell State, Cancer Stem Cells and Metastasis | NIH | National Cancer Institute | 2023 to 2025 | $1,766,080 | May 1, 2023 | April 30, 2028 | LANGENAU, DAVID MICHAEL | reporter.nih.gov |
| PennPET Explorer Scanner With Scalable Axial Length for Total Body PET Imaging | NIH | National Cancer Institute | 2021 to 2023 | $1,763,850 | December 5, 2018 | November 30, 2023 | KARP, JOEL S | reporter.nih.gov |
| Targeting EWS-ATF1 Fusion in Clear Cell Sarcoma of Soft Tissue | NIH | National Cancer Institute | 2022 to 2025 | $1,757,804 | December 1, 2021 | November 30, 2026 | LI, BINGBING | reporter.nih.gov |
| Phase I/II clinical trial of HDAC inhibition for GVHD prevention in children, adolescents, and young adults | NIH | National Cancer Institute | 2021 to 2024 | $1,755,671 | June 1, 2020 | May 31, 2026 | CHOI, SUNG WON | reporter.nih.gov |
| Targeting Microenvironmental Signals in Myeloid Malignancies | NIH | National Cancer Institute | 2022 to 2025 | $1,754,424 | July 1, 2022 | June 30, 2027 | BAJAJ, JEEVISHA | reporter.nih.gov |
| Principles of Speckle-Based Gene Regulation | NIH | National Cancer Institute | 2025 | $1,749,106 | August 5, 2025 | July 31, 2028 | ALEXANDER, KATHERINE ANN | reporter.nih.gov |
| Targeting allosteric scaffolding functions of Aurora kinase A in cancer | NIH | National Cancer Institute | 2021 to 2025 | $1,740,140 | April 1, 2021 | March 31, 2027 | LEVINSON, NICHOLAS MARK | reporter.nih.gov |
| Overcoming Leukemia Chemoresistance in the Central Nervous System | NIH | National Cancer Institute | 2021 to 2025 | $1,736,717 | March 4, 2020 | March 31, 2027 | GORDON, PETER M | reporter.nih.gov |
| Characterizing determinants of primary KSHV infection among children and adolescents in Uganda | NIH | National Cancer Institute | 2021 to 2023 | $1,735,566 | September 13, 2019 | August 31, 2025 | PHIPPS, WARREN | reporter.nih.gov |
| Discovery of small molecules targeting the histone acetylation reader ENL | NIH | National Cancer Institute | 2021 to 2024 | $1,734,163 | December 15, 2020 | December 1, 2025 | WEN, HONG | reporter.nih.gov |
| Cancer Immunotherapy Trials Network Central Operations and Statistical Center | NIH | National Cancer Institute | 2021 | $1,731,885 | September 22, 2010 | March 31, 2022 | DAVIDSON, NANCY ELLEN | reporter.nih.gov |
| Heterozygous KMT2D Loss and Medulloblastoma | NIH | National Cancer Institute | 2022 to 2025 | $1,730,741 | August 9, 2022 | July 31, 2027 | LEE, MIN GYU | reporter.nih.gov |
| Iomab-ACT: A phase I/II study of 131-I apamistamab targeted lymphodepletion followed by CD19-targeted CAR T-cell therapy for patients with relapsed or refractory B-ALL or DLBCL | NIH | National Cancer Institute | 2023 to 2024 | $1,730,616 | September 9, 2020 | July 31, 2025 | DESAI, AVINASH | reporter.nih.gov |
| Clinical, molecular, and immune characterization of naturally occurring osteosarcoma in dogs | NIH | National Cancer Institute | 2023 to 2025 | $1,729,726 | August 1, 2023 | July 31, 2028 | REBHUN, ROBERT B | reporter.nih.gov |
| Mechanisms of venetoclax combination activity in acute myeloid leukemia | NIH | National Cancer Institute | 2021 to 2025 | $1,729,672 | June 2, 2021 | May 31, 2026 | TYNER, JEFFREY WALLACE | reporter.nih.gov |
| PEDIATRIC ONCOLOGY EDUCATION (YEARS 38 - 42) | NIH | National Cancer Institute | 2022 to 2025 | $1,728,000 | July 1, 1978 | April 30, 2027 | GRONEMEYER, SUZANNE A. | reporter.nih.gov |
| Optimizing Carbon Ion Therapy for Pediatric CNS Tumors | NIH | National Cancer Institute | 2023 to 2025 | $1,727,977 | September 18, 2023 | August 31, 2028 | ELEY, JOHN G. | reporter.nih.gov |
| Intraoperative dual-labeled molecular tracer to improve surgery on neuroblastoma | NIH | National Cancer Institute | 2023 to 2025 | $1,724,101 | July 1, 2023 | June 30, 2028 | MALEK, MARCUS M. | reporter.nih.gov |
| Chemo-radio immunotherapy for pediatric brain tumors | NIH | National Cancer Institute | 2021 to 2023 | $1,721,832 | September 1, 2019 | August 31, 2025 | MUNN, DAVID H. | reporter.nih.gov |
| Targeting EGFR/FOXG1-mediated resistance to ONC201 in H3K27M-mutant diffuse midline glioma | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,721,391 | February 1, 2022 | January 31, 2027 | KOSCHMANN, CARL J | reporter.nih.gov |
| Novel Small-Molecule Probes Targeting Oncogenic Fusion MLL in Pediatric Leukemia | NIH | National Cancer Institute | 2022 to 2025 | $1,719,656 | December 10, 2021 | November 30, 2026 | SONG, YONGCHENG | reporter.nih.gov |
| Genetics and epigenetics of pediatric germ cell tumors | NIH | National Cancer Institute | 2022 to 2025 | $1,715,480 | September 1, 2022 | August 31, 2027 | POYNTER, JENNY N. | reporter.nih.gov |
| Understanding the immune response changes to clinical interventions for Epstein-Barr virus infection prior to lymphoma development in children after organ transplants (UNEARTH) | NIH | National Cancer Institute | 2024 to 2025 | $1,709,513 | September 1, 2023 | August 31, 2028 | DHARNIDHARKA, VIKAS R. | reporter.nih.gov |
| Metabolic adaptation in lymphoid malignancies | NIH | National Cancer Institute | 2021 to 2024 | $1,709,232 | December 1, 2019 | November 30, 2025 | ZHANG, JI | reporter.nih.gov |
| Identifying and Targeting the Drivers of Pediatric Brain Tumors | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,704,698 | October 1, 2022 | April 30, 2029 | WECHSLER-REYA, ROBERT J. | reporter.nih.gov |
| Novel functions of CDK6 in T-cell leukemia progression | NIH | National Cancer Institute | 2021 to 2025 | $1,701,837 | August 1, 2021 | July 31, 2026 | WANG, HAIZHEN | reporter.nih.gov |
| Engineered Ensemble Nanoimmunotherapies for Cancer | NIH | National Cancer Institute | 2021 to 2024 | $1,699,559 | February 1, 2023 | January 31, 2025 | FERNANDES, ROHAN | reporter.nih.gov |
| Role of Protein Arginine Methyltransferase 9 in Acute Myeloid Leukemia Maintenance | NIH | National Cancer Institute | 2021 to 2024 | $1,695,047 | March 1, 2020 | February 28, 2025 | LI, LING | reporter.nih.gov |
| Role of the SWI/SNF complex in tumor suppression | NIH | National Cancer Institute | 2021 to 2025 | $1,690,815 | July 1, 2013 | January 31, 2029 | ROBERTS, CHARLES | reporter.nih.gov |
| Development of AMPK Inhibitors for the treatment of leukemia | NIH | National Cancer Institute | 2021 to 2025 | $1,690,278 | July 1, 2021 | June 30, 2027 | REIGAN, PHILIP | reporter.nih.gov |
| The role of inflammation in the regulation of immune response in acute myeloid leukemia | NIH | National Cancer Institute | 2023 to 2025 | $1,687,418 | July 6, 2023 | June 30, 2028 | AIFANTIS, IANNIS | reporter.nih.gov |
| Combinational Targeting the Feed-forward Epigenetic Circuitry in Mixed Lineage Leukemia | NIH | National Cancer Institute | 2021 to 2025 | $1,684,284 | December 1, 2023 | February 16, 2025 | CHEN, CHUN-WEI DAVID | reporter.nih.gov |
| Novel Immunomodulation and Facilitation of “Suppression Proof” CAR NK cell against Ewing sarcoma | NIH | National Cancer Institute | 2021 to 2023 | $1,683,725 | September 1, 2023 | August 31, 2025 | CRIPE, TIMOTHY P | reporter.nih.gov |
| Determining the Role and Targeting potential of Serine Metabolism in aggressive sub-types of Acute Myeloid Leukemia | NIH | National Cancer Institute | 2023 to 2025 | $1,682,310 | March 1, 2023 | February 29, 2028 | SYKES, STEPHEN MATTHEW | reporter.nih.gov |
| Validation of an aqueous humor liquid biopsy for molecular prognostication and monitoring of children with retinoblastoma. | NIH | National Cancer Institute | 2023 to 2025 | $1,681,542 | August 1, 2023 | July 31, 2028 | BERRY, JESSE L | reporter.nih.gov |
| Understanding Infantile Rhabdomyosarcoma Biology and Therapeutic Targets | NIH | National Cancer Institute | 2022 to 2025 | $1,673,106 | September 23, 2022 | August 31, 2027 | KENDALL, GENEVIEVE CLAIRE | reporter.nih.gov |
| HPV, HIV and Oral Microbiota Interplay in Nigerian Youth (HOMINY) | NIH | National Institute of Dental & Craniofacial Research | 2022 to 2023 | $1,672,805 | August 1, 2022 | July 31, 2024 | COKER, MODUPE | reporter.nih.gov |
| Tracking Therapy-Resistant Alterations in Childhood Acute Lymphoblastic Leukemia | NIH | National Cancer Institute | 2022 to 2025 | $1,672,253 | August 1, 2022 | July 31, 2027 | MA, XIAOTU | reporter.nih.gov |
| Self-Management of Adolescent and Young Adult Survivors of Childhood Cancer | NIH | National Institute of Nursing Research | 2021 to 2023 | $1,670,597 | December 28, 2018 | November 30, 2025 | SCHWARTZ, LISA A | reporter.nih.gov |
| The function and underlying mechanism of TET1 in myelodysplastic syndromes | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,663,013 | March 10, 2020 | December 31, 2023 | CHEN, JIANJUN | reporter.nih.gov |
| NP855 for Targeting Thyrointegrin αvβ3 receptors and Norepinephrine Transporter in Neuroblastoma Management | NIH | National Cancer Institute | 2024 to 2025 | $1,661,800 | September 19, 2024 | August 31, 2027 | DAVIS, PAUL | reporter.nih.gov |
| ASO and shRNA for targeting the oncogenic transcript driving fibrolamellar hepatocellular carcinoma | NIH | National Cancer Institute | 2021 to 2024 | $1,659,105 | June 1, 2020 | May 31, 2025 | SIMON, SANFORD M | reporter.nih.gov |
| Enhancer Dysregulation in AML | NIH | National Cancer Institute | 2021 to 2023 | $1,657,025 | March 1, 2019 | February 28, 2025 | DOU, YALI | reporter.nih.gov |
| Leveraging Tumor Suppressor Inactivation for Osteosarcoma Therapy | NIH | National Cancer Institute | 2021 to 2024 | $1,655,878 | July 1, 2021 | June 30, 2026 | HOANG, BANG H | reporter.nih.gov |
| Molecular epidemiology of acute lymphoblastic leukemia in children with Down syndrome | NIH | National Cancer Institute | 2023 to 2024 | $1,645,759 | August 3, 2020 | July 31, 2025 | RABIN, KAREN R | reporter.nih.gov |
| Deconvoluting the Ewing sarcoma genetic program using ancestry-informed human iPSC modeling | NIH | National Cancer Institute | 2023 to 2025 | $1,644,656 | April 7, 2023 | March 31, 2028 | WEBBER, BEAU RICHARD | reporter.nih.gov |
| Regulation, function, and the therapeutic potential of an oncogenic long noncoding RNA lnc-HLX-2-7 in group 3 medulloblastomas | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,640,984 | July 15, 2022 | June 30, 2027 | PERERA, RANJAN JOSEPH | reporter.nih.gov |
| Pneumatic Drill and Robot for MRI-Guided Pediatrics Long Bone Biopsy | NIH | National Cancer Institute | 2021 to 2023 | $1,638,868 | March 1, 2020 | August 31, 2025 | CLEARY, KEVIN R. | reporter.nih.gov |
| Mechanisms of resistance to WEE1 inhibition in Myc driven medulloblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,638,259 | April 1, 2015 | November 30, 2026 | VIBHAKAR, RAJEEV | reporter.nih.gov |
| Admixture analysis of acute lymphoblastic leukemia in African American children: the ADMIRAL Study | NIH | National Cancer Institute | 2021 to 2024 | $1,638,139 | August 1, 2020 | July 31, 2025 | SPECTOR, LOGAN G. | reporter.nih.gov |
| Enhanced radiotherapy for pediatric glioma via synthetic lethal vulnerabilities | NIH | National Cancer Institute | 2024 to 2025 | $1,637,935 | July 1, 2024 | June 30, 2026 | CHOWDHURY, DIPANJAN | reporter.nih.gov |
| The Role of Immature Tumor Subpopulations In Pediatric Rhabdomyosarcoma | NIH | National Cancer Institute | 2022 to 2025 | $1,636,159 | March 4, 2022 | February 28, 2027 | CHEN, XIANG | reporter.nih.gov |
| BET bromodomain inhibition as targeted therapy in acute myeloid leukemia | NIH | National Cancer Institute | 2021 to 2023 | $1,634,470 | April 1, 2013 | November 30, 2024 | VAKOC, CHRISTOPHER | reporter.nih.gov |
| Cellular and Molecular mechanisms of ATRA inhibition of osteoblast-induced MDS development | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $1,628,178 | February 15, 2021 | November 30, 2025 | KOUSTENI, STAVROULA | reporter.nih.gov |
| Using Information Technology to Improve Outcomes for Children Living with Cancer | NIH | National Cancer Institute | 2021 to 2024 | $1,628,167 | September 20, 2019 | December 31, 2025 | LAI, JIN-SHEI | reporter.nih.gov |
| Non-invasively extendable megaprosthesis | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 to 2024 | $1,621,828 | September 25, 2023 | July 31, 2026 | GORDON, JEFFREY DAVID | reporter.nih.gov |
| Lineage-specific signaling and targeting of PI3K gamma in myeloid malignancies | NIH | National Cancer Institute | 2022 to 2025 | $1,620,456 | April 1, 2022 | January 31, 2027 | WOOD, KRIS C. | reporter.nih.gov |
| Identifying host factors that block engraftment and progression of transmissible cancer as a model of AML | NIH | National Cancer Institute | 2022 to 2025 | $1,617,947 | January 1, 2022 | December 31, 2026 | METZGER, MICHAEL JEFFREY | reporter.nih.gov |
| Investigating the role of dysfunctional histone H3.3 in driving early neuronal development and pediatric high-grade gliomas | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,617,011 | June 1, 2021 | November 30, 2026 | HU, JIAN | reporter.nih.gov |
| A web-based patient-reported symptom monitoring and self-management portal for adolescent and young adult breast cancer survivors | NIH | National Cancer Institute | 2023 to 2024 | $1,613,871 | September 18, 2020 | August 31, 2025 | PARTRIDGE, ANN H | reporter.nih.gov |
| The Role of GABA Transaminase ABAT in Pediatric Brain Tumor Medulloblastoma Development and Spread | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,613,377 | June 1, 2023 | February 28, 2028 | NEMAN-EBRAHIM, JOSH | reporter.nih.gov |
| Modeling Retinoblastoma Initiation Using 3D-Retinal Organoids | NIH | National Cancer Institute | 2021 to 2024 | $1,605,471 | May 15, 2020 | April 30, 2026 | DYER, MICHAEL A | reporter.nih.gov |
| Dysregulated transcription processes in Ewing sarcoma | NIH | National Cancer Institute | 2021 to 2024 | $1,602,211 | May 1, 2020 | April 30, 2026 | BISHOP, ALEXANDER JAMES | reporter.nih.gov |
| Novel targeted therapy to reduce health disparities in pediatric leukemia | NIH | National Cancer Institute | 2023 to 2025 | $1,596,016 | June 1, 2023 | May 31, 2028 | DOVAT, SINISA | reporter.nih.gov |
| Exploring microRNA degradation in T-cell acute lymphoblastic leukemia | NIH | National Cancer Institute | 2023 to 2025 | $1,594,435 | July 1, 2023 | June 30, 2028 | XIE, MINGYI | reporter.nih.gov |
| Cell lineage as an indicator of immune response in neuroblastoma | NIH | National Cancer Institute | 2022 to 2025 | $1,593,136 | June 16, 2022 | May 31, 2027 | GEORGE, RANI E. | reporter.nih.gov |
| Mechanisms of aggressive Rhabdomyosarcoma. | NIH | National Cancer Institute | 2023 to 2025 | $1,592,991 | March 1, 2023 | February 29, 2028 | LANGENAU, DAVID MICHAEL | reporter.nih.gov |
| Mechanisms and Modeling of Neuroblastoma-Associated ATRX Alterations | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,591,835 | March 1, 2020 | December 31, 2024 | BERNSTEIN, EMILY | reporter.nih.gov |
| Chemical Genetic Approaches to Study Chromatin Complexes | NIH | National Cancer Institute | 2023 to 2025 | $1,590,400 | May 3, 2023 | April 30, 2028 | LIAU, BRIAN | reporter.nih.gov |
| Regulation of Angpt1 and DIPG blood-brain barrier integrity by H3K27M mutations | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,587,577 | December 15, 2021 | November 30, 2026 | PHOENIX, TIMOTHY N | reporter.nih.gov |
| Developing and validating race-specific cardiomyopathy risk prediction models in African American survivors of childhood cancer | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,586,554 | May 15, 2024 | April 30, 2028 | SAPKOTA, YADAV | reporter.nih.gov |
| Role of UHRF1 in osteosarcoma and its relationship to RB | NIH | National Cancer Institute | 2021 to 2023 | $1,573,144 | June 1, 2019 | May 31, 2025 | BENAVENTE, CLAUDIA ANDREA | reporter.nih.gov |
| Mechanism(s) of TAL1- and NOTCH1-mediated Leukemogenesis | NIH | National Cancer Institute | 2022 to 2025 | $1,571,361 | August 1, 2004 | June 30, 2027 | KELLIHER, MICHELLE ALICE | reporter.nih.gov |
| Mechanisms of immunosuppression in the development and progression of renal disease in Tuberous Sclerosis Complex | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,569,410 | April 5, 2023 | March 31, 2028 | HENSKE, ELIZABETH P | reporter.nih.gov |
| Role of meningeal lymphatic vasculature in neuroimmune communication development | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,566,735 | February 15, 2023 | January 31, 2028 | THOMAS, JEAN-LEON | reporter.nih.gov |
| BCL11B activation as an approach for enhancing the efficacy of immunotherapy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,566,114 | February 11, 2021 | July 1, 2024 | PAREKH, CHINTAN | reporter.nih.gov |
| Nongenotoxic conditioning for gene therapy and allogeneic transplantation in Fanconi anemia | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $1,563,164 | December 20, 2019 | November 30, 2025 | KIEM, HANS-PETER | reporter.nih.gov |
| Oncogenic tyrosine kinases inhibitors abrogate DNA repair and sensitive leukemias to PARP inhibitors | NIH | National Cancer Institute | 2021 to 2024 | $1,562,631 | April 1, 2020 | March 31, 2026 | SKORSKI, TOMASZ | reporter.nih.gov |
| Heat Shock Transcription Factor 1 Specifically Regulates AML Stem Cell Self-Renewal | NIH | National Cancer Institute | 2021 to 2024 | $1,558,730 | December 15, 2019 | May 31, 2025 | ZHAO, CHEN | reporter.nih.gov |
| Sonic Hedgehog Signaling in Neocortical Growth and Folding | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,554,342 | September 30, 2017 | December 31, 2028 | HAN, YOUNG-GOO | reporter.nih.gov |
| GEARBOx - a multisite clinical trial matching tool for children with relapsed or refractory cancer | NIH | National Cancer Institute | 2022 to 2024 | $1,551,911 | September 21, 2022 | August 31, 2025 | VOLCHENBOUM, SAMUEL | reporter.nih.gov |
| Targeting DNA repair to eradicate TKi-refractory/resistant CML and Ph+ALL | NIH | National Cancer Institute | 2021 to 2024 | $1,543,188 | August 12, 2014 | February 28, 2026 | SKORSKI, TOMASZ | reporter.nih.gov |
| Mitochondrial NAD+ in Acute Myeloid Leukemias | NIH | National Cancer Institute | 2023 to 2025 | $1,541,490 | August 24, 2023 | July 31, 2028 | CAMBRONNE, XIAOLU ANG | reporter.nih.gov |
| Decreasing Cardiometabolic Risk in Survivors of Childhood Cancer: Survivors engaged in Time-Restricted EatiNG after THerapy (STRENGTH) | NIH | National Cancer Institute | 2024 to 2025 | $1,538,728 | September 1, 2024 | August 31, 2029 | FRIEDMAN, DANIELLE | reporter.nih.gov |
| Defining the microenvironment that will enable a long-term bioprosthetic ovary transplant | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $1,533,689 | May 1, 2021 | April 30, 2027 | LARONDA, MONICA M | reporter.nih.gov |
| TAM receptor inhibition in NF1-associated peripheral nerve sheath tumors | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,531,238 | July 1, 2022 | June 30, 2027 | CLAPP, DAVID W | reporter.nih.gov |
| Precision Targeting of Myeloid Src-family Kinases in Acute Myelogenous Leukemia | NIH | National Cancer Institute | 2021 to 2023 | $1,530,763 | July 15, 2019 | June 30, 2025 | SMITHGALL, THOMAS E. | reporter.nih.gov |
| Detecting DICER1: A global partnership to cure pediatric lung cancer | NIH | National Cancer Institute | 2021 to 2025 | $1,529,269 | February 15, 2020 | January 31, 2026 | SCHULTZ, KRIS ANN PINEKENSTEIN | reporter.nih.gov |
| Dependency of AML on CARM1 activity | NIH | National Cancer Institute | 2021 to 2024 | $1,525,290 | July 1, 2020 | June 30, 2026 | NIMER, STEPHEN D. | reporter.nih.gov |
| Role of TFEB and TFE3 in Tuberous Sclerosis Complex (TSC) Kidney Disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $1,521,682 | September 1, 2022 | April 30, 2026 | HENSKE, ELIZABETH P | reporter.nih.gov |
| Targeting the Microenvironment/Oncogene Cooperation to treat poor prognosis T-ALL | NIH | National Cancer Institute | 2023 to 2025 | $1,520,378 | March 9, 2023 | February 29, 2028 | CARLESSO, NADIA | reporter.nih.gov |
| Molecular mechanisms of nucleic acid machines | NIH | National Institute of General Medical Sciences | 2021 to 2024 | $1,520,008 | June 1, 2020 | May 31, 2026 | ENEMARK, ERIC | reporter.nih.gov |
| Targeting Shared Vulnerabilities in Alternate Telomere Lengthening (ALT) Cancers | NIH | National Cancer Institute | 2022 to 2025 | $1,509,510 | January 1, 2022 | August 31, 2027 | REYNOLDS, CHARLES PATRICK | reporter.nih.gov |
| Trajectory of epigenetic aging and health outcomes in childhood cancer survivors | NIH | National Cancer Institute | 2024 to 2025 | $1,509,154 | May 1, 2024 | April 30, 2026 | NESS, KIRSTEN KIMBERLIE | reporter.nih.gov |
| Molecular understanding of leukemic bone marrow cytokine-Ras signals and metabolic dependence | NIH | National Cancer Institute | 2022 to 2025 | $1,507,401 | July 1, 2015 | December 31, 2026 | ROOSE, JEROEN | reporter.nih.gov |
| Stage-specific roles for Zmiz1 in Notch-dependent steps of early T-cell development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,506,076 | June 1, 2019 | May 31, 2025 | CHIANG, MARK Y | reporter.nih.gov |
| Identifying opportunities for extracellular inhibition of ALK signaling | NIH | National Cancer Institute | 2021 to 2024 | $1,505,804 | September 1, 2020 | May 31, 2025 | KLEIN, DARYL EWALD | reporter.nih.gov |
| Nanoformulated small molecule immunotherapy for SHH medulloblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,504,463 | January 1, 2022 | December 31, 2026 | SOKOLSKY-PAPKOV, MARINA | reporter.nih.gov |
| Dual Kinase and LSD1 Inhibition in Acute Myeloid Leukemia | NIH | National Cancer Institute | 2023 to 2025 | $1,503,951 | July 13, 2023 | June 30, 2028 | BRAUN, THEODORE PAUL | reporter.nih.gov |
| Multiplex Epitope Editing to Enable Novel Immunotherapies for Acute Myeloid Leukemia | NIH | National Cancer Institute | 2024 to 2025 | $1,502,277 | July 3, 2024 | June 30, 2029 | GENOVESE, PIETRO | reporter.nih.gov |
| Epigenetic modulation of the TAZ-CAMTA1 transcriptional program by the Ada2a-containing histone acetyltransferase complex | NIH | National Cancer Institute | 2021 to 2024 | $1,500,569 | December 15, 2019 | November 30, 2025 | TANAS, MUNIR | reporter.nih.gov |
| Clinical & Mechanistic underpinnings to reducing PAX:FOXO1 for alveolar rhabdomyosarcoma | NIH | National Cancer Institute | 2021 to 2025 | $1,491,560 | May 14, 2021 | April 30, 2026 | KELLER, CHARLES | reporter.nih.gov |
| The Role of the CBFB-MYH11 Complex in Leukemia Maintenance | NIH | National Cancer Institute | 2021 to 2024 | $1,488,680 | April 1, 2020 | March 31, 2026 | HYDE, RICIA KATHERINE | reporter.nih.gov |
| Clinical Implications of Natural Killer-derived exosomal miRNAs in Neuroblastoma | NIH | National Cancer Institute | 2024 to 2025 | $1,485,440 | April 1, 2024 | March 31, 2029 | FABBRI, MULLER | reporter.nih.gov |
| Gene Expression Signature Based Screening in Ewing Sarcoma | NIH | National Cancer Institute | 2021 to 2024 | $1,484,581 | February 1, 2023 | January 31, 2026 | GORDON, DAVID J | reporter.nih.gov |
| Regulation of the Hedgehog pathway and Medulloblastoma response to radiochemotherapy | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,482,576 | April 15, 2021 | February 28, 2027 | PEI, HUADONG | reporter.nih.gov |
| Promoting immunity against acute myeloid leukemia through Fc effector-optimized antibody inhibitory of MICA/B shedding | NIH | National Cancer Institute | 2023 to 2025 | $1,481,935 | February 6, 2023 | November 30, 2027 | FERRARI DE ANDRADE, LUCAS | reporter.nih.gov |
| Unravelling metabolic dependencies in H3K27M mutant DIPG | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,480,728 | September 1, 2019 | August 31, 2029 | VENNETI, SRIRAM | reporter.nih.gov |
| Dissecting and targeting canonical and non-canonical oncogenic functions of EZH2 in caner | NIH | National Cancer Institute | 2023 to 2025 | $1,480,550 | January 1, 2022 | December 31, 2026 | WANG, G GREG | reporter.nih.gov |
| Targeting AVIL, a novel oncogene in rhabdomyosarcoma | NIH | National Cancer Institute | 2023 to 2025 | $1,479,063 | January 1, 2023 | December 31, 2027 | LI, HUI | reporter.nih.gov |
| Investigating novel synthetic lethal epigenetic interactions in Acute Myeloid Leukemia | NIH | National Cancer Institute | 2022 to 2025 | $1,477,105 | December 13, 2021 | November 30, 2026 | SHI, JUNWEI | reporter.nih.gov |
| Strategies to target BCR-ABL1 compound mutants in CML and Ph+ ALL | NIH | National Cancer Institute | 2022 to 2025 | $1,475,782 | November 10, 2021 | June 30, 2026 | DEININGER, MICHAEL W. | reporter.nih.gov |
Organizations
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 880 | $519,368,007 | 0 | $0 |
| 2024 | 942 | $507,315,115 | 0 | $0 |
| 2023 | 910 | $488,601,957 | 0 | $0 |
| 2022 | 898 | $454,265,211 | 0 | $0 |
| 2021 | 830 | $430,105,501 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.